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Abstract
Oral delivery is the most preferred route of administration of drugs by the
patients. When a drug is taken orally, its absorption will occur in the
small intestine as it provides a high surface area. For example, low gastric
pH, enzymes and mucus layer can have a negative impact on the admin-
istered active pharmaceutical compound (API). Excipients, mucoadhesive
and enteric coatings, and permeation enhancers are all common strategies
to facilitate the delivery of the API. Nevertheless, these approaches are not
always enough making necessary the development of new oral drug delivery
systems.
Recently, microfabricated devices have been explored as alternative oral
drug delivery systems to enhance release and absorption of drugs. One of
these systems is microcontainers which are polymeric cylindrical microde-
vices fabricated in epoxy-based photoresist SU-8. They have an external
diameter and height of approximately 300 µm. Contrary to the omni-
directional release that is characteristic of loaded formulation tablets, cap-
sules and particulate systems, the unidirectional release provided by micro-
containers avoids loss of the API in the lumen.
In this project, the work focused on two main aspects i) loading tech-
niques for enhancing oral delivery of poorly water soluble drugs and ii)
coating the cavity of microcontainers in order to functionalize these for in-
creasing the oral absorption of proteins. In order to enhance the release and
absorption of poorly soluble drugs, they were loaded into microcontainers
with either polyvinylpyrrolidone (PVP) or polycaprolactone (PCL). It has
been showed in vitro that the loading technique influences the release of
the poorly soluble model drug ketoprofen even when loaded with the same
polymer (PCL). In particular, the distribution of the ketoprofen or naproxen
loaded into the PVP matrix using supercritical scCO2 (scscCO2 ) impregna-
tion was evaluated. This was possible using a custom-made Raman system,
where volumetric Raman maps of a whole microcontainer were obtained.
These analyses showed that the drug was on top of the polymer even when
the area exposed to the scscCO2 was changed. Such results confirmed and
explained the fast release profiles obtained by in vitro analyses. These stud-
ies were followed by in vivo experiments in rats to fully understand the
behavior of the microcontainers in vivo. These studies showed an enhanced
vii
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relative oral bioavailability compared to control samples. For oral protein
delivery, microcontainers were loaded with the model protein, lysozyme to-
gether with a permeation enhancer (sodium decanoate). The loaded micro-
containers were functionalized by applying on their cavity two polymeric
coatings. The idea was to enhance the protein delivery and mucoadhesion
of the microcontainers. For these reasons, the first coating was poly(lactic-
co-glycolic (PLGA) and on top of this either chitosan or polyethylene glycol
(PEG) was applied. The functionalization was evaluated in vitro for mor-
phology, drug release and mucoadhesive properties. These were coupled with
in vitro and ex vivo studies using cell models and porcine intestinal tissue.
This showed that microcontainers can be functionalized with bi-layer lids
facilitating tunable protein release as well as improved mucoadhesion of the
microcontainers.
In conclusion, techniques for loading microcontainers with poorly water
soluble drugs were compared and characterized. Moreover, microcontainers
were functionalized for oral delivery of protein. These results showed a
promising potential for microcontainers as oral delivery system for poorly
soluble drugs and proteins. Further optimization of the microcontainers
and their characterization techniques are however still required in order to
improve their efficacy and flexibility.
Resume´
Oral levering af lægemidler er den foretrukne administrationsvej for pa-
tienter. N˚ar et lægemiddel indtages oralt, vil dets optagelse forekomme i
tyndtarmen, da der her er et stort overfladeareal. For eksempel kan lav
pH i maven, enzymer og mucus-laget have en negativ indvirkning p˚a det
administrerede lægemiddelstof. Hjælpestoffer, mucoadhæsive og enteriske
overtræk og absorptionsfremmere er alle fælles strategier for at lette lev-
eringen af et lægemiddelstof. Ikke desto mindre er disse metoder ikke altid
nok, og dette gør det nødvendigt at udvikle nye orale leveringssystemer for
lægemidler.
For at forbedre frigivelse og absorption af lægemidler er man for nylig
begyndt at undersøge mikrofabrikerede enheder som et alternativt lever-
ingssystem for lægemidler. Et af disse systemer er mikrocontainere, som er
polymeriske cylindriske mikroenheder fremstillet i epoxybaseret fotoresist
SU-8. De har en ydre diameter og en højde p˚a ca. 300 µm. I modsæt-
ning til den omni-direktionelle frigivelse, som er karakteristisk for formuler-
ingstabletter, kapsler og partikelformede systemer, undg˚ar den ensrettede
frigivelse, muliggjort af mikrocontainere, tab af API’en i lumen.
Dette projekt var fokuseret p˚a to hovedaspekter i) Loading teknikker til
forbedring af oral administrerede lægemidler med lav vandopløselighed og
ii) Belægning af mikrocontainernes hulrum for at funktionalisere disse og
dermed øge den orale absorption af proteiner. For at forbedre frigivelsen
og absorptionen af lægemidler med lav vandopløselighed, blev de loaded i
mikrocontainere lavet af enten polyvinylpyrrolidon (PVP) eller polycapro-
lacton (PCL). In vitro studier har vist, at forskellige loading teknikker har
indflydelse p˚a frigivelsen af det lavt-opløselige medikament ketoprofen, p˚a
trods af loading med den samme polymer (PCL). Især blev fordelingen af
ketoprofen eller naproxen, loaded i PVP-matrixen med superkritisk CO2
(scCO2) imprægnering, evalueret. Dette var muligt ved at anvende et
skræddersyet Raman-system, hvor der blev opn˚aet volumetriske Raman-
kort af hele mikrocontainere. Disse analyser viste, at lægemidlet var oven
p˚a polymeren, selvom omr˚adet udsat for scCO2 blev ændret. Disse re-
sultater bekræftede og forklarede de hurtige frigivelsesprofiler set ved in
vitro analyser. Disse undersøgelser blev fulgt af in vivo forsøg i rotter,
for fuldt ud at forst˚amikrocontainernes funktion in vivo. Disse studier
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viste en forbedret relativ oral biotilgængelighed sammenlignet med kon-
trolprøver. Til oral administration af proteiner blev mikrocontainerne fyldt
med modelproteinet lysozym samt en permeationsforstærker (natriumde-
canoat). De fyldte mikrocontainere blev funktionaliseret ved p˚a førelsen af
to polymere belægninger p˚a hulrummet. Ideen var at øge mikrobeholderens
proteinafgivelse og mucoadhæsion. Derfor brugte vi poly (lactic-co-glycolic
(PLGA) til første overtræk, hvorefter enten chitosan eller polyethyleng-
lycol (PEG) blev p˚aført. Funktionaliseringen blev evalueret in vitro for
morfologi, frigivelses- og mucoadhæsive egenskaber. Disse forsøg blev sam-
menkoblet med in vitro- og ex vivo-undersøgelser i cellemodeller og porcin
tarmvæv. Disse forsøg viste, at mikrocontainere kan funktionaliseres med to-
lags overtræk, der faciliterer fleksibel proteinfrigivelse, samt forbedre mikro-
containernes mucoadhæsion.
I konklusion teknikker til loading af lægemidler med lav-vandopløselighed
i mikrocontainere blev sammenlignet og karakteriseret. Desuden blev mikro-
containerne funktionaliseret til oral levering af protein. Disse resultater viste
at mikrocontainere har et lovende potentiale som oral administrationsvej for
d˚arligt opløselige lægemidler og proteiner. Yderligere optimering af mikro-
containerne og deres karakteriseringsteknikker er dog stadig nødvendig for
at forbedre b˚ade effektivitet og fleksibilitet.
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Chapter 1
Introduction
Oral administration is the preferred route of administration for the patient,
due to its low invasiveness compared to other routes which require, for ex-
ample, the use of needles [1]. Between 2013 and 2018 almost 50% of the
approved pharmaceutical formulations on the market and more than 40%
of the products in pipeline are for oral drug delivery [2]. These percentages
indicate that there is a big market and a wide interest in oral drug delivery
research.
Design of an oral drug delivery formulation can be rather complex. De-
spite the fact that the gastrointestinal (GI) tract has a total surface of 1000
m2, representing a unique interface between the external environment and
the interior of the body, its anatomy and physiology represent an obsta-
cle for pathogens and toxins as well as drugs [3]. The fluids in the GI
tract, the presence of mucus and the intestinal cell barrier all cause big
challenges to overcome, especially for specific active pharmaceutical ingre-
dient (API)s, like poorly water soluble drugs and therapeutic peptides and
proteins [4, 5]. The most common parameter to evaluate if an oral phar-
maceutical product is effective is called oral bioavailability. It indicates the
ratio between the amount of API reaching the systemic circulation and the
dose administered [6]. For all the reasons mentioned above, approximately
50% of the APIs suffer from low oral bioavailability [7]. The strategies to
overcome such problems are multiple and every API requires a different for-
mulation, with specific features to improve its oral bioavailability. The most
common approaches include excipients, permeation enhancers, micro- and
nanoparticulate systems, drug modification, protein inhibitors and enteric
or mucoadhesive coatings [7, 8, 9, 10, 11].
All the aforementioned approaches are not always enough to enhance the
oral uptake. In this project, microfabricated devices called microcontainers
are proposed as carriers for APIs. These microdevices have a cylindrical
shape and a cavity which can be used for the loading of APIs. One of the
biggest and most important differences compared to traditional oral drug
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delivery systems is that microcontainers allow unidirectional drug release,
since only one surface of the microdevice can open. This feature can reduce
the loss of API in the lumen [12]. It was observed that microcontainers
engulf themselves in the intestinal mucus [13]. This phenomenon allows mi-
crocontainers to be closer to the intestinal barrier than formulations staying
in the lumen. Moreover, coatings can be applied on top of the microsized
cylinders to release the API in the area of interest, most often the intestine
[13].
Before the start of this project, various studies have been conducted in
order to discover and characterize the potential of microcontainers for oral
drug delivery. The most relevant, in respect to this project, is the one car-
ried out by Nielsen et al., which showed that microcontainers improved the
relative oral bioavailalbility of furosemide (Class IV in the Biopharmaceutics
Classification System (BCS)) in vivo compared to the drug in a capsule [13].
In the pharmaceutical field, all the loading techniques developed and
commonly used are for traditional drug delivery systems, such as tablets
and micro- and nanoparticles. Although microcontainers showed several
advantages, their loading can be challenging, since it can be done only from
the top, thus requiring great geometrical accuracy and correct alignment of
the loading system. In addition, the loading technique needs to be repro-
ducible, avoid drug degradation and waste and, for some APIs, control the
solid form of the drug. Therefore, an important study for this project is
related to the characterization of a loading technique for microcontainers.
This allowed the loading of a poorly water soluble drug into microcontain-
ers and the contemporary transformation of a drug into its amorphous state
[14].
These studies were the starting points of this project, leading it to explore
and compare different loading techniques and to use microcontainers as an
oral delivery system for proteins.
1.1 Aims of the project
The aims of this PhD project were to apply microcontainers as oral delivery
systems for i) poorly soluble drugs and ii) therapeutic peptides and proteins.
To improve the bioavailability of poorly soluble drugs, microcontainers
should i) be loaded with a formulation that improves solubility and stability
of the API and ii) be sealed with coatings preventing enzymatic degrada-
tion and release in the stomach. For these reasons, the focus was on the
comparison and characterization of techniques used for the loading of mi-
crocontainers. In addition, various combinations of polymer excipients and
poorly soluble drugs were evaluated.
As regards to the delivery of therapeutic peptides and proteins, micro-
containers should i) contain a permeation enhancer to help the protein being
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transported across the intestinal wall, ii) be functionalized to improve the
release of the protein in the intestinal environment and iii) be coated with
a mucoadhesive polymer to have a release in proximity to the intestinal
barrier. In this case, the approach is directed to the functionalization of
microcontainers, in order to provide mucoadhesiveness and an enhancement
of the protein absorption. To this end, particular focus was devoted to the
characterization of the polymers used for the double coating of the micro-
containers.
To achieve these goals, two major accomplishments needed to be com-
pleted. First, loading techniques were tested and compared using, mainly, in
vitro release studies and, in case of drug distribution analyses, Raman spec-
troscopy. These were followed by in vivo studies. Second, microcontainers
needed to be functionalized for oral protein delivery. This included explor-
ing the possibility of applying more than one coating on the microcontainers
and to test them in vitro and ex vivo.
1.2 Outline of the thesis
This thesis is structured in seven chapters. This introductory chapter is fol-
lowed by four chapters providing the background and an overall description
of the PhD project. Specifically, Chapter 2 reports a brief description of the
advantages and challenges of oral drug delivery. In Chapter 3, challenges
and strategies used to orally deliver poorly water soluble drugs and ther-
apeutic proteins are presented, followed by a description of microdevices.
Chapters 4 presents microcontainers as an oral drug delivery system, de-
scribing the fabrication, loading and coating techniques. In Chapter 5, all
the characterization techniques for microcontainers used during the project
are illustrated. The on-going projects are briefly described in Chapter 6.
The thesis is completed with the conclusions and future perspectives in
Chapter 7.
In all the chapters, the terms “API” and “drug” have been used as syn-
onyms for simplicity. Moreover, for the same reason, “therapeutic peptides
and proteins” are often mentioned as either “peptides” or “proteins” accord-
ing to the context.
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Chapter 2
Oral drug delivery
A drug can be administered by different routes of administration. These are
defined as the path by which a drug is delivered in the body. By changing
this route, the number of biological barriers that the API must cross before
reaching the targeted area will change. The routes of administration can
be classified according to if they are invasive or not (Figure 2.1). Invasive
administration refers to, for example, intravenous, intramuscular and sub-
cutaneous routes. The non-invasive route are, for example, oral, nasal and
transdermal [15, 16].
Figure 2.1: Schematic of administration routes examples.
Oral drug delivery is the route in which the API is taken through the
mouth. Before entering into the portal circulation, from where the API will
reach the desired site, the drug is exposed to different environments [15].
The advantages and disadvantages of this route will be explained in the
following sections.
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2.1 Advantages
The oral route of administration is the most preferred route from the point
of view of the patient and therefore often leads to improved compliance [17].
The main reason for this is that swallowing a tablet is the same natural
action as swallowing foods or liquids. Moreover, compared to injections, the
oral route is painless and allows self-administration, with no need of training
or specialized personnel [1, 18]. Formulations for oral drug delivery do not
require strict sterility constraints as, for example, needles for intravenous
or intramuscular dosage forms allowing to have higher degree of flexibility
[19]. These formulations are also often easy to transport due to their sta-
bility. This is particularly advantageous in underdeveloped countries where
the means of transport are often poor. Consequently, for all the reasons
just mentioned, formulations for the oral route are most often the cheapest
among all the available dosage forms [20, 21] and the most preferred way to
administer APIs [17].
As mentioned in the introductory chapter, the GI tract, having a surface
area of around 1000 m2, provides a unique interface between the external
environment and the interior of the body. Nevertheless, the anatomy and
physiology of the GI tract present many obstacles that impair the absorption
of pathogens, toxins as well as drugs [3].
2.2 Challenges
The role of the GI tract is to digest liquids and food, absorb the nutrients
and excrete what is recognized as toxic for the body. Therefore, the GI tract
plays an important role in the oral administration of APIs. For this reason,
the drug formulation needs to be designed taking into account the physical
and chemical properties of the GI tract [22].
2.2.1 Gastrointestinal tract physiology
Orally administered drugs go through the GI tract, which is divided into
the upper and lower tract. The upper GI tract consists of the oral cavity,
esophagus, stomach, and the small intestine, whereas the large intestine and
the rectum are part of the lower GI tract (Figure 2.2) [3].
The digestion of food starts in the mouth where it is chewed and mixed
with degradation enzymes. However, the transit through the mouth is fast
and therefore the first organ they encounter for digestion is the stomach.
Gastric acid and digestive enzymes break down the ingested food to allow it
to pass through the pyloric sphincter and enter into the small intestine. The
pH values in the GI tract can vary according to diet, age and sex. In the
fasted state, in the stomach, the pH is below 3 (Table 2.1) and therefore only
few molecules are absorbed there [23]. The small intestine is designed for
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Figure 2.2: Anatomy of the human GI tract. The main GI areas interested in
the digestion and absorption are represented: esophagus, stomach, small intestine
(duodenum, jejunum and ileum) and large intestine (cecum, colon and rectum).
absorption of nutrients and is divided into duodenum, jejunum and ileum.
Duodenum is the first and shortest section (Table 2.1) in which the material
coming from the stomach is mixed with pancreatic digestive fluids and liver
bile. The material that is not absorbed in the small intestine, is led to the
colon through the ileocecal valve [24].
Table 2.1: Biological and physical parameters of all the gastrointestinal segments.
Adapted from [25, 26, 27].
Gastrointestinal
segment
Approximate
surface area
Approximate
segment length
Approximate
pH
Oral cavity 100 cm2
Esophagus 200 cm2 23 - 25 cm
Stomach 3.5 m2 0.25 cm < 3
Duodenum 1.9 m2 0.35 m 6.4
Jejunum 184 m2 2.8 m 7
Ileum 276 m2 4.2 m 7.3
Colon and rectum 1.3 m2 1.5 m 5.7 - 6.6
In fact, 90% of the absorption takes place in the jejunum and ileum
and this is due to, among others factors, the large surface area and the high
density of enzymes. The internal surface of the small intestine presents three
types of projections: plicae, villi and microvilli; all three increase the surface
area of the small intestine by 3, 30 and 600-fold, respectively (Figure 2.3)
8 Chapter 2. Oral drug delivery
[28, 29]. Overall, the surface area of duodenum, jejunum and ileum is around
500 m2 (Table 2.1). Enzymes are responsible for breaking down proteins into
small peptides and amino acids, lipids into fatty acids and glycerol, and some
carbohydrates into simple sugars or monosaccharides [25]. The absorption
is also assisted from peristaltic movements that are particularly pronounced
in the small intestine [30]. The large intestine is responsible for absorbing
water and, therefore, solidification of the content into feces [30].
Figure 2.3: Illustration of the composition of the small intestinal walls. From left:
the plicae, villi and microvilli. They are responsible for increasing the absorption
area by 3, 30 and 600 fold, respectively. Reprinted from [31] with permission.
2.2.2 Mucus layer
The internal surface of the GI tract is covered by mucus, produced mainly
by goblet cells. The mucus consists of more than 98% of water together
with various mucin glycoproteins, enzymes and electrolytes [28, 32]. The
most important structural component of the mucus gel are the mucin glyco-
proteins giving it its characteristic gel-like, adhesive and cohesive properties
[33]. The mucus has different thicknesses and roles in the stomach, small
intestine and colon (Figure 2.4).
In some areas, mucus is composed of two layers, one that is firmly ad-
herent (closer to the epithelium) and one that is loosely adherent. In the
small intestine, the mucus provides a diffusion barrier since it usually fills
the luminal space between and on top of the villi [34]. Therefore, the de-
signed API formulation needs to reach the epithelial layer penetrating the
mucus.
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Figure 2.4: Schematic of the thicknesses of the loosely adherent and firmly adher-
ent mucus layers measured in the stomach, duodenum, jejunum, ileum and colon of
a rat. The adherent mucus layer is close to the epithelium and the loosely adherent
layer is on top. The table shows the mean of the mucus thickness as µm ± SD.
Reprinted from [34] with permission.
2.2.3 Cellular pathways for absorption
After penetrating the mucus, the compound needs to be transported across
the epithelial barrier to be able to reach the portal circulation. This bar-
rier is composed of a single layer of epithelial cells which, depending on the
GI area, vary in number. In the small intestine, the enterocytes are the
most abundant cell type and they are responsible for the absorption of nu-
trients from the intestine into the blood stream. Other cells are interspersed
together with enterocytes in the small intestine (Figure 2.5) [32]. For ex-
ample, goblet cells secrete mucus and paneth cells, antibacterial peptides
and proteins (Figure 2.5) [32]. All of these cell types and many others are
connected with tight junctions creating a separation barrier between the
luminal material and the subepithelium [35].
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Figure 2.5: Schematic representing the epithelial barrier showing enterocytes, gob-
let and paneth cells covered by mucus layer.
There are two main pathways by which an API can pass from the in-
testinal lumen to the underlying tissue and into circulation; paracellular
transport which is between the cells and transcellular transport where the
transport is through the cells (Figure 2.6) [28, 30].
Figure 2.6: Schematic representing the main pathways for an API to pass from
the intestinal lumen to the underlying tissue and circulation: paracellular (left) and
transcellular (right) pathways.
Transcellular transport is associated with solute transport through the
epithelial cells and mainly regulated by selective transporters for amino
acids, electrolytes, sugars and short chain fatty acids. This pathway can also
be passive when small lipophilic molecules pass through the cell membrane
[36]. The paracellular transport is regulated by intercellular complexes,
called tight junctions, placed at the apical-lateral membrane junction and
along the lateral membrane. For this type of uptake, tight junctions have a
fundamental role since they seal the intercellular space, thereby functioning
as a selective paracellular barrier [37]. These junctions facilitate ions and
solute passage through the intercellular space preventing, at the same time,
antigens or toxins to enter [35]. The hostile acidic environment in the stom-
ach, the high enzymatic activity in the small intestine and the intestinal
mucosa barrier are inherent features that need to be kept in consideration
when designing a drug formulation for oral delivery [28].
Chapter 3
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The challenges for oral drug delivery, discussed in the previous chapter,
have particularly an impact on specific groups of drugs like, poorly water
soluble drugs, and therapeutic proteins and peptides. In the next sections,
the reasons of their low bioavailability and strategies commonly applied to
improve it will be described. Moreover, microdevices will be described as an
alternative and more recent way to deliver poorly soluble drugs or proteins,
and to further enhance their bioavailability.
3.1 Poorly water soluble drugs
Considering that solubility and intestinal permeability are the main factors
affecting oral bioavailability, the U.S. Food and Drug Administration (FDA)
provided the BCS as a guide to predict the intestinal drug absorption (Figure
3.1) [38]. In general, solubility is defined as the property of a solid, liquid or
gaseous chemical substance (solute) to dissolve in a solid, liquid or gaseous
solvent and form a homogeneous solution of the solute in the solvent [38].
According to the BCS, a drug is classified as highly soluble, when the highest
therapeutic dose of the drug is soluble in 250 mL or less of water with a pH
ranging from 1 to 7.5. The intestinal permeability, instead, is a classification
in which the orally administered compound is compared with the intravenous
injection. The BCS divides all drugs in four classes (Figure 3.1). In case
of an API with high permeability, it belongs to Class I if it is highly water
soluble or in Class II if it is poorly soluble. Instead, when the drug is poorly
permeable, it is part of Class III when it is highly soluble and Class IV when
it is poorly soluble [39].
Regardless of the great number of novel drug molecules in pipeline, only a
few of them have reached the market. This is due to several factors including
lack of efficacy, safety and low bioavailability (accounting for around 40%
of failures) [40]. Moreover, around 40% of marketed drugs and 70% of
compounds currently under development are poorly soluble drugs meaning
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that there is a huge need to enhance the solubility of these compounds
[41, 42, 43]. If the solubility of the API is low, the desired concentration
in the systemic circulation, and consequently, the required pharmacological
response are not reached. To overcome this issue, poorly soluble drugs often
require higher doses to be able to reach the therapeutic plasma concentration
[38].
Figure 3.1: Schematic of the Biopharmaceutics Classification System (BCS) in
which drugs are divided in four classes according to their aqueous solubility and
intestinal permeability.
3.1.1 Strategies to improve bioavailability
Solving the solubility issue is one of the biggest challenges for formula-
tion scientists. Depending on the properties of the API and its needed
dosage, several techniques have been developed to enhance the solubility
[44]. According to the type of modification, these techniques can be di-
vided in three categories [45] (Figure 3.2). Physical modifications refer to
changes at the particulate level as particle size reduction, amorphous sys-
tems and metastable polymorphs. When the modifications are at a molecu-
lar level, they are cassified as chemical modifications including, for example,
salt formation, prodrugs, cyclodextrins and co-solvents. The third category
is comprised of alterations at the colloidal level such as lipid formulations,
emulsions and self-emulsifying drug delivery systems [38, 42]. Amorphous
systems are one option among all the modifications (Figure 3.2). They can
be easy to obtain and their missing lattice structure make them more wa-
ter soluble than the ordered crystal lattice. However, these drugs are not
stable in their amorphous form and tend to crystallize. One solution to sta-
bilize them and to improve their solubility is to form solid dispersion with
polymers [44].
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Figure 3.2: Schematic representing the type of modifications to enhance solubility
of poorly soluble APIs and their examples.
Solid dispersions
A solid dispersion was in 1971 defined by Chiou et al. as “the dispersion of
one or more active ingredients in an inert carrier or matrix at solid state”
[46]. Preparing solid dispersions is a common technique for poorly water
soluble drugs since they can stabilize the amorphous form of a drug [41, 47].
This improved stability is due to the fact that the solid dispersion presents a
higher glass transition temperature (Tg) that reduces the molecular mobil-
ity at storage temperature [44]. Another reason for the enhanced stability
is claimed to be the polymer-drug interactions in the solid dispersion. They
often form hydrogen-bond which prevents the crystal growth of the amor-
phous drug [44, 48].
In this project, the aim was to obtain amorphous API and to do that,
poorly soluble drugs such as ketoprofen and naproxen were coupled with
polymer matrixes (polyvinylpyrrolidone (PVP) or polycaprolactone (PCL))
forming a solid dispersion. In the next section, drugs and polymers used
will be described.
3.1.2 Ketoprofen and naproxen
Ketoprofen and naproxen belong to Class II in the BCS and their water
solubility is 15.9 mg/L (at 25 °C) and 51 mg/L (at 22 °C) [49], respectively.
They are both propionic acid derivates and nonsteroidal anti-inflammatory
drugs (NSAID) with anti-inflammatory, analgesic and antipyretic effects
[50]. These APIs are used in the treatment of rheumatoid arthritis and
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osteoarthritis. In this thesis, ketoprofen has been used as poorly water sol-
uble model drug in Paper I, II and III, whereas naproxen has been used in
Paper II.
3.1.3 Polyvinylpyrrolidone and polycaprolactone
PVP and PCL are widely used polymers in the pharmaceutical field. FDA
approved PVP for oral drug delivery [51] and PCL for application used in
the human body like drug delivery devices and sutures [52]. PVP is often
used as an excipient in formulations due to its amorphous nature, high Tg
and the ability to form hydrogen bonds with many APIs. Moreover, due to
its high water solubility, it improves the solubility and stability of the drug.
However, due to its hygroscopic property, care needs to be taken to avoid
moisture uptake in the formulation [45].
PCL is a semicrystalline polymer with a melting temperature in the
range of 59 - 64 °C depending on the crystallite size [52]. This polymer is
known to be degradable at a slow rate, therefore being a good candidate
for controlled release formulation or implantable long-term biostable drug
delivery sytems [53]. In Paper I, PCL has been used together with keto-
profen to test two different loading techniques for microdevices. PVP was
loaded with ketoprofen or naproxen to evaluate the loading technique called
supercritical CO2 (scCO2) impregnation that will be described in the next
chapter.
PCL (in Paper I) and PVP (in Paper II and III) were used as excipients
in formulations for oral drug delivery of the poorly water soluble drugs
ketoprofen or naproxen.
3.2 Therapeuthic peptides and proteins
Proteins are biological macromolecules able to perform vital functions in the
body. They are formed by amino acids which are linked together forming
a linear chain called primary protein structure. This chain can form other
shapes defined as secondary, tertiary and quaternary structures [54]. Pep-
tides are distinguished from proteins according to the number of amino acids
by which they are composed. By definition, a peptide is formed by 50 or
less amino acids [55].
Human insulin is one of the oldest protein and since the discovery of
its recombinant form in 1978 and its FDA approval in 1982, the success of
proteins has grown constantly [56, 57]. Better understanding of biochem-
istry and molecular biology, has opened up the enormous potential of the
therapeutic use of proteins and peptides [58, 59].
Treatments with proteins are more effective compared to conventional
small molecule drugs when administered for similar treatments [58] leading
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to less chance of adverse effects and interference with normal biological pro-
cesses. As many of the proteins used in treatments are naturally produced
by the body, they are most often well-tolerated and are less prone to elicit
immune responses [60]. As discussed previously, the oral route remains the
most attractive route of administration for drugs [59]. In general, however,
this route is not always feasible for protein-based drugs [61]. Despite their
benefits, at present, protein and peptide drugs are mainly administered ei-
ther subcutaneously or intramuscularly [58]. One of the reasons for this
is that proteins are mostly hydrophobic and large molecules. This hinders
their passive diffusion through the transcellular pathway [62]. However, pas-
sage via the paracellular pathway is usually restricted to molecules in the
size range of 100-200 Da (molecular radii lower than 11 A˚), by the narrow
space between adjacent enterocytes. Therefore, lipophilic molecules usually
utilize the transcellular pathway and hydrophilic molecules the paracellular
pathway (Figure 3.3) [62].
Figure 3.3: Schematic representation of the steps for oral protein absorption. 1)
Transit in the stomach: degradation in acidic environment. 2) Transit in the GI
fluids: degradation by enzymes. 3) Residence time in the window of absorption.
4) Diffusion through the mucus layer. Transport across the cellular barrier through
5a) transcellular pathway or 5b) paracellular pathway.
Generally, there is an undiminished ambition in overcoming the obstacles
of oral protein delivery [63]. Thus, various strategies have been explored to
target both the transcellular and paracellular pathways [63] with the use of
specialised drug delivery systems [64].
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3.2.1 Strategies to improve bioavailability
There are several approaches to enhance the oral bioavailability of therapeu-
tic proteins including the use of enzyme inhibitors, absorption enhancers and
mucoadhesive polymers (Table 3.1) [65].
Table 3.1: Approches used in oral protein delivery to improve their absorption
together with their outcomes and possible drawbacks.
Approches Outcome for absorption Drawbacks
Enzyme
inhibitors
Resist enzyme degradation
occuring in the stomach and
in the intestine
Induce severe
side effect in
chronic therapy
Absorption
enhancers
Increase membrane
permeation
Uptake of
undesired molecules
present in the
GI tract
Mucoadhesive
polymers
Protect drug from acid
and luminal proteases
in the GI tract and enhance
permeation
Time limitation
due to the natural
mucus turnover
in the intestine
As aforementioned, proteins are broken down from the digestive system
into simpler molecules like amino acids and sugars that are easily absorbed.
The responsibles for the cleavage of the amino acid chains are the enzymes
like trypsin, chymotripsin, elastase and pepsin [66]. Enzyme inhibitors pro-
tect the protein from degradation by enzymes in the stomach and intestine.
This can be a drawback in case of repeated drug delivery since protease in-
hibitors can prevent the absorption of other proteins and, therefore, induce
toxic effects [66].
The absorption enhancers transport proteins directly through the epithe-
lium without major effects on their solubility [67]. They can be classified
as either increasing the paracellular permeability or the transcellular per-
meation [66]. However, one of the biggest drawbacks is that the addition
of a permeation enhancer in a formulation enhances the transport of not
only the desired protein but also undesired molecules present in the GI
tract [65]. Bile salts and fatty acids are the most common enhancers and,
in this project, sodium decanoate (C10) has been used in Paper IV. C10
is a saturated fatty acid and it is one of the most researched permeation
enhancer [68]. The World Health Organization (WHO) and FDA have ap-
proved it as a food additive without daily limit. It has been shown that its
effect is mainly on the paracellular pathways and that the effect is reversible
preventing undesired compound from crossing the epithelium layer [69].
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Mucoadhesive polymers, instead, can prolong the residence time at the
site of absorption creating contact with the mucus layer and increasing the
drug concentration gradient and, at the same time, reducing dilution or
degradation in the lumen. However, a limitation of this approach is the
natural mucus turnover in the intestine [65]. This topic will be discussed in
detail in Chapter 5.
3.2.2 Lysozyme
Lysozyme is a protein formed by 129 amino acids having a molecular weight
of 14.3 kDa. It is an antimicrobial enzyme and is a part of the innate immune
system. It is cheap and commercially available for pharmaceutical and food
applications for cancer chemotherapy and for antimicrobial approaches. This
enzyme can be responsible for hydrolysis of the cell wall of a Gram-positive
bacteria. Lysozyme has been used in Paper IV as a model protein.
3.3 Microdevices
Oral drug dosage forms are mainly and traditionally in powder forms and
compressed to tablets [70]. In the last decades, an alternative approach
has been to use micro- and nanoparticles which required the exploration
of different types of polymers and techniques [65]. The main drawbacks of
these particulate systems and tablets are the lack of protection from the
gastric environment and the direction of release. In fact, the API is released
equally in all directions, exposing the API to the lumen and not only to the
cell membrane (Figure 3.4) [65].
Figure 3.4: Schematic representation of API release differences between micropar-
ticulate system (left) and microdevices (right).
Moreover, in case of micro- or nanoparticles, the surface area exposed to
the intestinal wall, due to their spherical shape, is limited. The dimensions of
the particles can vary significantly and with it, the quantity of loaded API
[12]. Recently, microdevices have been proposed as alternative oral drug
delivery system (Figure 3.4). One of the main advantages in deploying mi-
crodevices is the unidirectional release of the loaded formulation. Moreover,
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the microstructure protects the drug from three sides against, for example,
low pH and enzymes, limiting the loss and degradation of the API [12].
Microdevices have been fabricated using different fabrication techniques.
Depending on the material, the geometry, shape, reservoir volume and size
desired, it is possible to choose among photolithography, soft lithography,
hot embossing and hot punching and stamped assembly of polymers layers
(Figure 3.5) [12].
Figure 3.5: Schematic representation of the main fabrication techniques for mi-
crodevices with images as examples. Reprint from [12] with permission.
In the last decades, different fabrication techniques for several types of
microdevices have been developed. Poly(methyl methacrylate) (PMMA)
microdevices were fabricated using photolithography and lectins (proteins
capable of targeting the cells on the intestinal wall) were attached to modify
them chemically. The bioadhesive property was tested in vitro [71]. Planar
microdevices for oral drug delivery were described as oral drug delivery
system enhancing 4.5-fold the oral bioavailability in vivo of acyclovir, a
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poorly water soluble drug [72]. Sealed nanostraw microdevices were made
in PMMA, PCL, polycarbonate (PC) and aluminium oxide. The nanostraws
facilitated API loading and enhanced the adhesion of the device to intestinal
tissue [73].
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Chapter 4
Microcontainers for oral
drug delivery
In the previous chapters, the importance of designing an optimal formu-
lation for oral drug delivery has been explained, as well as the strategies
to enhance the oral bioavailability of formulations for poorly water solu-
ble drugs and therapeutic proteins. In this thesis, microcontainers have
been used and characterized as carriers for formulations of poorly soluble
drugs and therapeutic proteins. Microcontainers are polymeric cylindrical
microdevices with only the top side open (Figure 4.1) which can be loaded
with a desired API using various techniques. In the next chapter, the coating
of microcontainers and subsequent functionalization will be discussed.
Figure 4.1: a) Schematic and b) scanning electron microscopy (SEM) image of a
microcontainer. The scale bar represents 100 µm.
In previous works, it has been showed that microcontainers can: i) be
fabricated in different sizes according to specific requirements [74], ii) stabi-
lize the amorphous state of a loaded API [74], iii) enhance the oral bioavail-
ability of furosemide [13, 75] and iv) be filled with PVP and loaded with
ketoprofen using scCO2 getting the drug in its amorphous form [14]. In
the next section, the different steps used in this project in order to prepare
formulations using microcontainers will be discussed.
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4.1 Fabrication
Since the early nineties, SU-8 has been used as thick-film resist for the
fabrication of microstructures with thicknesses of hundreds of micrometers.
It was chosen as material for the fabrication of microcontainers due to its
chemical resistance, structural stability and biocompatibility [76]. Microcon-
tainers are fabricated with an accurate and controllable fabrication process.
As shown in Figure 4.2, their fabrication is based on a two-step photolithog-
raphy process of SU-8 on 4-in Si wafers.
Figure 4.2: A schematic overview of the fabrication process: a) spin coating of
the resist on silicon (Si) wafer, b) mask alignment, ultraviolet (UV) exposure and
development, and c) spin coating, mask alignment, exposure of the second resist
layer and development. Reprinted from [77] with permission.
At the end of the process, on each wafer, 18750 microcontainers are made
and divided in smaller squares (chips) to ease subsequent handling (Figure
4.3). On every chip, there are 625 microcontainers and each squared chip
has the dimensions of 12.8 x 12.8 mm2. When not specified, microcontainers
have a height and diameter of around 300 µm. However, in specific projects,
the size and number of microcontainers per chip has been changed according
to the needs.
For example, in Paper I, due to the chosen loading technique, the height
was 100 µm. In Paper II, instead, the sizes have been changed to obtain
three different sizes of microcontainers to evaluate the loading technique. In
that case, their diameters varied from 200 µm (small size) to 500 µm (large
size) all having 300 µm as height.
According to the type of experiment and application, it was necessary
to detach the microcontainers from the Si substrate. In this case, specific
materials were deposited between the Si and the SU-8 microcontainers (Fig-
ure 4.4). In Paper III, poly(acrylic acid) (PAA), being water soluble, has
been used as previously described by Linder et al. as a sacrificial layer for
4.2. Loading methods 23
Figure 4.3: Photo of a whole 4-inches wafer with 18750 microcontainers fabricated
and zoom in of one single chip with 625 microcontainers.
fabrication of microstructures [78]. Therefore, microcontainers detach from
the Si chip when soaking the chip in water (Figure 4.4a). In Paper IV,
fluorocarbon (Fc) was used as layer in between the SU-8 microcontainers
and the Si (Figure 4.4b). Fc is an anti-stiction coating and it has been
showed that a Fc surface has good properties for releasing SU-8 devices as
cantilevers and membranes in the micrometer range [79]. Moreover, Nielsen
et al. used microcontainers with this layer underneath allowing for easy
manual detachment from the chip [80].
Figure 4.4: Schematic representation of layers to detach microcontainers from
the Si substrate: a) in purple the dissolving PAA layer in water detaching the
microcontainer, b) in yellow a representation of the Fc anti-stiction layer.
4.2 Loading methods
Despite all the advantages described for microcontainers, compared to tra-
ditional formulations like particulate systems or tablets, their loading can
be rather complex. This is due to the fact that the loading can be made
only through the cavity hole on top and needs to be quite accurate and
reproducible. In case of liquids, the capillary forces may make difficult or
hinder their loading. As described in the previous chapter, in case of poorly
water soluble drugs, the formulation design is of fundamental importance.
Therefore, it is relevant to choose the right excipients to improve solubility
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and, at the same time, stabilize the amorphous state of the BCS Class II
APIs. In particular, in Paper I, II and III, the focus has been on the load-
ing techniques. Instead, in Paper IV, since the API to load was a model
protein, the attention was more on the coatings and functionalization of the
microcontainers.
4.2.1 Powder loading methods
Most of the commercially available APIs are in powder form and, therefore,
a method for filling powder into the microcontainers is really essential. The
first method used to fill microcontainers was a simple manual filling. With
this method, the drug was deposited on top of the chip and with a finger or
a brush, the powder was pushed into the microcontainers. To remove excess
powder between the microcontainers, an air gun was used (Figure 4.5).
Figure 4.5: Representation of the manual loading technique for loading microcon-
tainers. The powder is pushed into the microcontainers using a brush or a finger
(middle) and the excess of powder is removed using an air gun (right).
This process can present some limitations: i) if the powder is sticky, it is
difficult to remove it from the space between the microcontainers, ii) if the
powder is not fine, the pressure of a finger or brush might not be enough to
push it inside and iii) the powder can be expensive and, therefore, blowing
the excess away can be costly. For these reasons, Abid et al. developed
a filling method to improve the loading of powders [70]. In Figure 4.6, it
is showed how the microcontainers chip (Figure 4.6b) can be placed in an
alignment tool (Figure 4.6c) to allow alignment of a shadow mask on top
(Figure 4.6a). The shadow mask covers the space between the microcontain-
ers thereby reducing powder waste. In this way, the chip with the clamped
mask can be placed on top of a powder layer (Figure 4.6d). Pressure can
either be applied manually or by deploying a bonding press to push the
powder into the microcontainers in a controllable and reproducible manner
(Figure 4.6e) [70].
In Paper II and III, the simple method without mask has been used since
PVP needed to be filled and its powder is dry, cheap and has a small particle
size. In Paper IV, the mask was used together with a brush to reduce the
waste of lysozyme between the microcontainers and to fill them applying
low pressure to prevent potential denaturation of the protein.
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Figure 4.6: Representation of the clamping system for the shadow mask (a) onto
the chip of microcontainers (b) that is placed in an alignment tool (c). (d) The
chip with the mask is placed on top of a powder layer and (e) pressed into it. (f)
The mask is removed and the microcontainers are loaded. Reprinted from [70] with
permission.
4.2.2 Supercritical CO2 impregnation
Carbon dioxide (CO2) is non-flammable, inexpensive and chemically inert
making it a widely used solvent. In addition, it is available at high purities
and has low toxicity. It is defined as a “green” alternative compared to the
traditional organic solvents since it is not defined as a volatile substance and
does not have any restriction regarding food or pharmaceutical applications
[81, 82]. ScCO2 impregnation exploits the supercritical state of CO2. When
a substance reaches the critical point, gas and liquid merge together in
a homogeneous phase called the supercritical phase (Figure 4.7) [83]. In
particular, a supercritical fluid (SCF) can be defined as a substance at a
temperature and pressure higher than their critical values having a density
close or higher than its critical density [84]. SCFs are characterized by a
density close to a liquid and viscosity and diffusivity similar to a gas.
The combination of the CO2 and SCFs properties makes scCO2 a good
solvent for various applications [82]. The critical point of CO2 is 73.8 bar
and 31.1 °C [83]. ScCO2 is a good solvent for many non-polar low molecular
weight compounds. It alters density, diffusivity and swells polymers having,
consequently, a huge plasticizer potential that usually would require higher
temperatures [82]. Due to the mild conditions required, scCO2 is suitable
for thermolabile API; indeed, scCO2 has been extensively used in the phar-
maceutical industry for drug delivery systems, precipitation processes and
powder processing [85].
One application is related to solid dispersions for oral drug delivery, in
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Figure 4.7: Schematic pressure-temperature phase diagram for a pure compound
showing the SCF region. The triple point T and critical point C are marked in
green. The blue circles represent the variation in density of the substrate in the
different regions of the phase diagram. Reprinted from [83] with permission.
which one compound is a polymer, defined as matrix, and the other is an
API that needs to be impregnated into the matrix. For this application, the
polymer needs to be insoluble in scCO2 although swelling is required to allow
for the scCO2 to permeate the matrix. To design a good formulation, it is
fundamental to choose the right drug/polymer combination. For example,
scCO2 has been used to impregnate PVP microparticles with ketoprofen
[86].
Figure 4.8: Representation of the high pressure chamber during the scCO2 im-
pregnation of the PVP filled into the microcontainers with ketoprofen. Reprinted
from Paper III [87] with permission.
In the case of microcontainers, a PVP matrix (PVP) has been filled into
the microcontainers and then loaded with ketoprofen using scCO2 [14, 82].
As it can be seen in the Figure 4.8, the PVP filled microcontainers were
4.2. Loading methods 27
placed in the high pressure chamber on a grid to allow magnets to stir during
the impregnation process. Together with the chips, the drug in powder form
is poured into the chamber. The chamber has a heating system temperature
control. Once the samples are inside, valves are opened to fill the chamber
with CO2. The pump is programmed to reach the desired pressure with
a specific flow rate. When the supercritical phase is reached, a magnetic
stirrer is activated to increase the movement inside the chamber. At the
end of the process, the chamber is depressurized by opening the outlet valve
(Figure 4.9).
Figure 4.9: Schematic of the scCO2 impregnation system used in this project.
In Paper II, this loading technique for naproxen and ketoprofen has been
characterized evaluating the effect of the surface area of microcontainer cav-
ities exposed to the scCO2 on the API distribution and loaded amount. In
Paper III, scCO2 was used to load microcontainers for in vivo studies.
4.2.3 Hot-punching of polymer films
The name hot-punching indicates the combination of heating and pressure.
This technique has been previously used by Petersen et al. to fabricate
microstructures using biodegradable polymers like poly(lactic acid) (PLLA).
The fabrication was performed by heating the polymer above its Tg and
applying a pressure so that the Ni stamp could cut the polymer and obtain
the desired microstructure [88, 89].
In this project, microcontainers have been used as molds to fill their
cavities. The polymer or polymer+API solutions were spin coated on a Si
wafer. The microcontainers were placed on top and due to heating and
pressure, the microcontainer walls were able to cut the polymer layer.
From a previous study, it was shown that when ketoprofen is impreg-
nated in PVP filled into microcontainers, its release was rapid [77]. There-
fore, in Paper I, ketoprofen was loaded into PCL to evaluate if a less water
soluble polymer could result in a different release of ketoprofen from the
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microcontainers. In particular, in Paper I, two loading techniques were com-
pared. In one case, microcontainers were loaded by hot-punching a layer of
PCL+ketoprofen, in the second case, microcontainers were filled only with
PCL by hot-punching and ketoprofen was then impregnated with scCO2.
4.3 Coating polymers and techniques
In the previous sections, fabrication of microcontainers and different loading
methods have been discussed. In Paper III and IV, the focus has also been
on the coating of microcontainers. In particular, in Paper III the aim was to
test in vivo if the microcontainers could enhance the oral bioavailability of a
poorly soluble drug like ketoprofen. Microcontainers were therefore coated
with a pH-sensitive polymer to prevent release of ketoprofen in the stomach.
The focus in Paper IV was on how to functionalize the microcontainers for
oral protein delivery. In the following section, polymers relevant for this
project as well as the coating deposition technique will be introduced.
4.3.1 pH-sensitive coatings
In Chapter 1, while describing the GI tract, the difference of pH in the
different segments was discussed. The values presented were from human
fasted patients, but they depend on the ingested food and liquids, age, and
sex [23]. In addition to that, there are differences in the pH of the GI tract
among species. Therefore, it is important to consider this before designing
a formulation. In Paper III, for example, we chose to test the formulation
using Sprague-Dawley rats. From the pH values in the Table 4.1, it was
possible to decide which polymer was relevant to use.
Table 4.1: pH values in the stomach and in the proximal small intestine measured
in rats and humans. Adapted from [90, 91].
GI segment pH in rats pH in humans
Stomach 1.4 - 1.9 1.7 - 3.3
Proximal small intestine 6.7 - 7.0 5.6 - 7.8
pH-sensitive coatings are commonly used for overcoming the degradation
of APIs in the stomach (Figure 4.10). Since the aim of this study was to
test the microcontainers behavior in vivo, Eudragit L100 (Evonik, Germany)
was chosen becuase it is a well tested and used polymer. The Eudragit
products are synthetic polymers based on poly(meth)acrylate chemistry and,
depending on the functional groups, the polymer can tune the release. In
this project, since the release was aimed to happen in the intestine the
Eudragit L100 has been chosen since it dissolves at pH higher than 6.
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In Paper III, Eudragit L100 coating protected the loaded formulation in
two occurrences: during the preparation of microcontainer formulation and
during the in vivo experiments. Once the microcontainers had been man-
ually filled with PVP, ketoprofen was loaded using scCO2 impregnation.
Eudragit L100 was then deposited on top to protect the load. Microcon-
tainers needed to be detached from the chips to be filled into the capsules for
oral gavage. Therefore, the chips were soaked in water in pH 3.25, at which
the coating is insoluble. In this way, the PAA layer dissolved, releasing the
microcontainers without compromising the coating (Figure 4.4a). Micro-
containers were then filled into capsules and the formulation was ready to
be dosed via oral gavage to the rats. This coating prevented the release of
ketoprofen in the stomach of rats after administration (Figure 4.10). The
same polymer has been used for the control formulation in order to evaluate
if the microcontainers could enhance the oral bioavailability of the poorly
soluble drug ketoprofen.
Figure 4.10: Microcontainer with coating in the stomach and dissolution of the
lid in higher pH in the small intestine where release and absorption are desired.
4.3.2 Coatings for therapeutic proteins
In Chapter 3 and Table 3.1, different strategies to enhance the oral bioavail-
ability of therapeutic proteins were discussed. In this section, the impor-
tance and the mechanism of mucoadhesive polymers and other coatings will
be explained.
Bioadhesion is the generic word defining the state at which two materi-
als (at least one of which biological) are held together by interfacial forces
for an extended period of time. When the adhesive layer is mucus, this
phenomenon is called mucoadhesion [33]. When designing a formulation for
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oral drug delivery of proteins, a common strategy is the use of mucoadhe-
sive polymers to increase the residence time at the site of absorption. These
polymers keep a close contact with the intestinal mucus to increase the drug
concentration gradient without degradation or dilution in the luminal fluid
[65].
In Paper IV, three different polymers were chosen for microcontainer
coating: chitosan, polyethylene glycol (PEG) and poly(lactic-co-glycolic)
acid (PLGA). In the following sections, all of these will be described. A
schematic representation of microcontainers coated with two of the chosen
polymers for oral protein delivery is shown in Figure 4.11.
Figure 4.11: Schematic representation of microcontainers coated with two polymer
layers for oral delivery of the model protein lysozyme (Paper IV). a) Microcontainer
coated with PLGA and chitosan and b) microcontainer coated with PLGA and PEG.
Poly(lactic-co-glycolic) acid (PLGA)
PLGA is a copolymer of poly lactic acid (PLA) and poly glycolic acid (PGA)
(Figure 4.12) [92]. In its dry state, PLGA is generally stable, but when
exposed to aqueous environments such as the in vivo environment, it will
degrade (Figure 4.12) [93]. This degradation occurs by hydrolysis and it
is firstly broken down into small oligomers and further into its monomers.
Eventually, these hydrolysis products are metabolized and cleared from the
body with minimal systemic toxicity associated (Figure 4.12) [92].
Figure 4.12: The degradation process of PLGA into its monomers by hydrolysis.
PLGA is considered one of the most successfully developed and used
polymers owing to its very attractive properties [94]. It is biodegradable,
biocompatible, approved by FDA and European Medicines Agency (EMA),
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and is very well studied [95, 96]. This means that formulations and produc-
tion methods are well-described in combination with different types of drugs,
hydrophobic and hydrophilic small molecules, as well as macromolecules.
PLGA’s attributes have been utilized to protect drug molecules from degra-
dation and facilitating sustained release. Finally, PLGA can be used to
modify surface properties of biological materials [92].
Chitosan
Chitosan (Poly-(D)glucosamine) is obtained by partial or full deacylation
of chitin (a long-chain polymer of N-acetylglucosamine). Chitin is a nat-
ural polysaccharide produced by a vast number of living organisms such
as fungi, crustaceans and insects [97]. Chitosan exists in many molecular
weights and degrees of deacetylation (40 - 98%) which influences its viscosity
and solubility properties including mucoadhesion [98, 99]. The pKa value of
the primary amine of glucosamine is approximately 6.5. Consequently, chi-
tosan is primarily protonated in acidic pH and soluble in the cationic form
[100]. Therefore, generally, chitosan is soluble in aqueous acidic solutions
and dimethylsulfonide [101].
Chitosan is well-known as a mucoadhesive agent, enabling longer res-
idence time in the small intestine [102]. This property makes chitosan a
popular polymer to include in drug delivery systems [102]. Chitosan’s mu-
coadhesive properties arise from its strongly positive charge, attracting the
negatively charged mucins of the mucus [103]. Chitosan has the capability to
form both hydrogen bonds and covalent bonds, via its -OH and -NH2 groups.
This enables an electrostatic interaction with the negatively charged mucus
components such as sialic acid [98]. In addition, hydrophobic interactions
play a role in mucoadhesive properties of chitosan [104].
In Chapter 3, the importance of permeation enhancers has been dis-
cussed. In Paper IV, C10 has been loaded together with the model protein
lysozyme and chitosan was one of the coating layers. In fact, its proto-
nated form has demonstrated the ability to increase paracellular permeabil-
ity across mucosal epithelia for macromolecules [98]. It does so by reversibly
modulating the integrity of the epithelial tight junctions [102]. The signal
mechanism by which chitosan induces opening of tight junctions has been
studied and found that multiple mechanisms may be involved in the process
[102, 105]. Results indicate that chitosan interacts with the transmembrane
claudin protein CLDN4 to trigger the opening of tight junctions [105, 106].
Polyethylene glycol (PEG)
One of the most used polymers in drug delivery systems is the FDA ap-
proved PEG. It is a relatively chemically inert and non-biodegradable poly-
mer. It is uncharged and amphiphilic, meaning that it is both hydrophilic
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and hydrophobic in nature. Consequently, it is soluble in water and organic
solvents [107]. Furthermore, PEG has good mucolytic properties, retention
effects and it is widely used and studied as a mucoadhesive agent [108].
The mucoadhesive properties are believed to arise from its hydrophilic na-
ture and ability to inter-diffuse with the mucus gel network. The molecular
weight and density of PEG seem to play a role in its interaction with the
mucus mesh. A high molecular weight of PEG increases mucoadhesion and
a transition has shown to appear in the range of 5 to 10 kDa, where PEG
changes from being mucopenetrating to mucoadhesive [109]. Higher molec-
ular weights of PEG present longer chains resulting in better entanglement
with mucins, increasing the number of intermolecular interactions such as
hydrogen bonding [110].
4.3.3 Coating deposition techniques
There are different well established techniques for coating deposition. In
the pharmaceutical field, the most common ones are: conventional pans,
perforated pans and fluidized beds (Figure 4.13). In all cases, a polymer
solution is delivered through a spray nozzle and deposited onto a sample.
The coating liquid is atomized with air and the substrate moves in order to
coat the whole sample surface.
Figure 4.13: Schematic representation of a) coating pan and b) fluidized bed coat-
ing systems. Reprinted from [111, 112] with permission.
Although the coatings obtained with these techniques are reproducible
and are used in large scale processes, they are not suitable for coating micro-
containers. This is because microcontainers need to be coated only on their
top, where the cavity is and, consequently, an ultrasonic coating system has
been chosen in this project.
Ultrasonic coating system
In an ultrasonic coating system, the polymer solution is sprayed through
an ultrasonic nozzle that moves in x-y-z directions over a sample (Figure
4.14a). The sample is placed on a heating plate in which the temperature
can be controlled enhancing, for example, the solvent evaporation.
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Figure 4.14: a) Drawing of the ultrasonic coating system for coating the cavity
of the microcontainers with polymers. Reprinted from [113] with permission. b)
Schematic representation of the two spray paths over the microcontainer chip.
Every coating technique has several parameters that need to be adjusted
in order to obtain a uniform spray. In case of the ultrasonic coating system,
these are the power of the ultrasound generator, the atomizer pressure and
the syringe pump flow [113]. Once the spray is uniform, an area where the
sample is placed can be defined. The nozzle moves in “arcs” as shown in
Figure 4.14b. For this reason, to obtain a more homogeneous coating, in
Paper III and IV, two similar areas were selected with an offset in the x
direction (Figure 4.14b). Moreover, the distance between the nozzle and the
sample, the nozzle speed, the temperature of the substrate and how many
times the nozzle follows the two areas are all important parameters to obtain
a uniform coating layer [113].
If the coating displays cracks, a plasticizer like triethyl citrate, propylene
glycol or dibutyl sebacate (DBS) needs to be added to the polymer solution.
A plasticizer can change thermal and mechanical properties of a polymer
lowering, for example, its rigidity at room temperature [114]. For this reason,
in Paper III, DBS was added to the Eudragit L100 coating solution.
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Chapter 5
Characterization and
evaluation techniques for
microcontainers
Characterizing the microcontainers is of utmost importance to evaluate that
the design and fabricated formulation provide the desired features. In the
next sections, the main methods used to characterize and evaluate the mi-
crocontainers are briefly described.
5.1 Drug quantification
The amount of loaded API is commonly evaluated placing the sample in a
buffer solution or biorelevant medium and measuring the drug release over
time. The most common measurement method is ultraviolet-visible (UV-
vis) spectrophotometry [115, 116].
The light is an electromagnetic radiation characterized by waves having
different lengths or number of photons with different energy. UV-vis spec-
trophotometry includes the wavelength range 190 - 800 nm being from 190
to 400 nm the UV region and from 400 to 800 nm the visible range. The
absorption of light happens when the energy from the photon stimulates
an electron to reach a higher energy state. The capability of a molecule
to absorb light as a function of wavelength is expressed in a UV-vis ab-
sorption spectrum. This ability depends on the molecular structure of the
compound. The Lambert-Beer’s law quantitatively describes the absorption
of UV and visible light associating the absorption of light from a molecule
to its concentration. The law states that the absorbed light is proportional
to the number of functional groups and structural elements absorbing light
present in the medium in which the light is passing through. This means
that the amount of absorbed light is also proportional to the concentration
of the absorbing species. The law is valid in dilute solution if the light is
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monochromatic. It can be expressed with the following formula:
log10 (I0
I
) = log10 ( 1
T
) = A = εbc (5.1)
where I0 is the intensity of the incident light, I is the intensity of the trans-
mitted light, T is the transmittance given by (I/I0), A is the absorbance, ε
is the molar absorption coefficient (L mol-1 cm-1), b is the light path and c
is the concentration of the absorbing molecule (mol L-1) [115, 116].
5.1.1 µDiss profiler
In this project, UV spectrophotometry has been used in all Papers; in partic-
ular, the in vitro releases have been measured with an in situ UV fiber optic
monitoring system (µDiss profiler, pION INC) (Figure 5.1). The system
consists of a probe, which acts both as light emitter and receiver. The light
detection is guaranteed by a mirror placed at the end of the probe (Figure
5.1). When the probe is submerged into the solution, the analyte absorbs
some of the emitted light. As the concentration of the analyte increases,
the intensity of light reflected back into the probe by the mirror decreases
(Equation 5.1) [117, 118].
Figure 5.1: Schematic representing a glass vial with the in situ UV probe, a
magnetic stirrer and a microcontainer chip for in vitro measurements. The zoomed
figure represents the release of the compound from the microcontainers and the
mirror of the in situ probe for absorbance measurements.
To determine the behavior of drugs in vitro, simple buffer solutions like
phosphate-buffered saline (PBS) are widely used. To better simulate the
in vivo scenario, it is important to choose media having similarities to gas-
trointestinal fluids. Several media have been proposed to simulate gastric
and duodenal conditions and their compositions have been adjusted based
on in vivo measurements [119]. In Paper III, to test the performance of the
pH-sensitive coating, biorelevant media simulating the fasted gastric and
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intestinal fluids were used (Biorelevant®). These media, containing tau-
rocholate, phospholipids, sodium, chloride and phosphate, better represent
key aspects of the GI fluids. The key features that need to be considered
are, for example, osmolality, ionic strength, viscosity and surface tension
[120, 121].
5.1.2 High performance liquid chromatography (HPLC)
In Paper III and IV, high performance liquid chromatography (HPLC) was
used to analyze samples from in vitro studies, ex vivo transport studies,
and plasma samples from in vivo studies. With this technique, before the
detection, the sample undergoes separation. This happens in a column (Fig-
ure 5.2) where the analytes distribute between the mobile and the station-
ary phases thereby getting separated. The most commonly used HPLC
technique is the reversed phase, in which the stationary column is more hy-
drophobic than the mobile phase (called reversed phase-HPLC (RP-HPLC)).
With this technique, there can be different kinds of detectors such as UV,
fluorescence and mass spectrometry [122, 123]. In this project, a UV detec-
tor was used.
Figure 5.2: Schematic representing a HPLC system.
5.2 Morphology characterization
5.2.1 Scanning electron microscopy (SEM)
Since microcontainers are three dimensional (3D) structures, to evaluate
their loading and coating, the use of a SEM microscope was suitable com-
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pared to optical microscopy (Figure 5.3a-b). SEM is a well established tech-
nique for investigating the morphology of 3D samples like microcontainers.
Scanning the sample surface, the electron beam penetrates it creating the
image by collecting electrons that interact with the specimen.
Figure 5.3: Comparison between microcontainer images obtained with a) optical
microscopy and b) SEM. c) Schematic representation of interacton of the secondary
electrons with the sample surface, when it is flat and in case of a protrusion.
The most suitable detector in the pharmaceutical field is the one col-
lecting data from secondary electrons (SE). These electrons generate an
interaction volume in the sample but only those in close vicinity (several
nm) to the surface can leave the sample due to their low energy. Conse-
quently, in protruding areas of the specimen the number of SE that leave
the surface is higher than in flat areas (Figure 5.3c). In the SEM image, the
protruding areas appear brighter than the others creating a 3D effect on a
two dimensional (2D) image with high topography resolution (Figure 5.4)
[124].
Moreover, for this project, the use of a tilted stage (30°) or the possibility
of rotating it was of essential importance to be able to evaluate the level of
loading and coating homogeneity on the microcontainer cavities (Figure 5.4).
Figure 5.4: SEM images of microcontainers that allow to evaluate a) thin and b)
thick coatings.
5.2.2 X-ray micro computed tomography (X-ray µCT)
In Paper I, III and IV, SEM images were not sufficient to evaluate various
steps of the microcontainer preparation. X-ray micro computed tomography
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(X-ray µCT) can be used to analyze the cross-section of a sample. In this
technique, the x-rays are used to obtain the cross-section without cutting
and, therefore, without destroying the sample [125, 126]. The images and
videos used in this work are the result of a collaboration with the Senior Re-
search Engineer Carsten Gundlach from DTU Physics who measured all the
samples for the project. With X-ray µCT, it was possible to determine if the
loading reached the bottom of the microcontainers (Paper I), to study the
level of homogeneity of the coatings (Paper III and IV), and to investigate
if microcontainers filled into the capsules were intact (Paper III).
5.3 Solid state characterization
In Chapter 4, the importance of the solid state of poorly soluble drugs
has been described. The physical state of poorly soluble drugs can influence
their solubility and dissolution rate [127]. Consequently, after characterizing
the fabrication and loading of microcontainers, the solid state of the API
was evaluated. In the pharmaceutical field, there are many techniques to
evaluate the solid state of an API and, in this project, Raman spectroscopy
and x-ray powder diffraction (XRPD) have been used in Paper I, II and III.
5.3.1 Raman spectroscopy
In the previous sections, light absorption has been described for a quanti-
tative analyses of a compound in solution, but the light interaction with a
molecule can happen either through emission or scattering [128]. The scat-
tering phenomena can be elastic or inelastic, defined as Rayleigh and Raman
scattering, respectively. The majority of photons hitting a sample undergo
elastic scattering (Rayleigh) where there is no energy transfer between the
photon and the sample (Figure 5.5) [129]. The remaining photons (one ev-
ery 106 photons) will transfer energy and give rise to inelastic scattering
(Raman) (Figure 5.5). The Raman signal is stronger with molecules having
electrons that are easy to polarize than those held tightly since its intensity
is proportional to the polarizability of the molecule [128].
A Raman spectrum represents a structural fingerprint by which it is pos-
sible to identify molecules. As most of the excipients used in the pharma-
ceutical field are σ-bonded molecules (e.g. starch and cellulose) and most of
the APIs contain pi-electrons, the Raman signal is generally strong for drugs
making it a suitable technique for such investigations [130]. Raman spec-
troscopy for this project was even more attractive since it is very versatile
allowing to measure a wide diversity of samples including the formulations
loaded into microcontainers [131].
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Figure 5.5: Jablonski diagram representing energy transition for infrared absorp-
tion, Rayleight, Stokes and anti-Stokes scattering.
5.3.2 X-ray powder diffraction (XRPD)
XRPD is one of the most straightforward analytical techniques for poly-
morph identification at the particulate level. It is useful for obtaining direct
information on the crystalline lattice. With this technique, a diffractiogram
is obtained [132]. These diffractograms consist of thousands of individual
measurements of x-ray intensities, made at regular intervals along an arc
that describes the angle of diffraction, 2θ, relative to the path of the in-
cident x-ray beam [133]. Peaks in the diffractogram are a result of the
diffraction of x-rays by atoms in the crystal structure and are most conve-
niently thought as x-ray reflections from individual lattice planes in the unit
cell. These reflections are observed only if the Bragg’s law is satisfied:
λ = 2dsinθ (5.2)
where λ is the incident x-ray wavelength, 2dsinθ the path difference between
two waves undergoing intereference. In principle, XRPD pattern contains
information regarding the internal arrangement of the material of interest
[132]. The size and shape of the unit cell can be determined by the peak po-
sitions in the diffractogram, while peak intensities can be used to determine
the types of atoms present in the cell and their positions [133]. The align-
ment of the particles in the preferred orientation in the XRPD holder can
significantly affect the location, area and intensity of the diffraction peak
[133]. Thus, quantitative analysis that involves intensity ratios or areas can
be greatly distorted by alignment of the crystallites in the preferred orien-
tation. In this project, only the qualitative analysis of the solid state forms
was of interest.
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5.4 Drug distribution
Raman spectroscopy, together with other techniques, has been widely used
to understand the distribution of compounds for example in 3D printed
tablets. Trenfield et al. cut a tablet and a 2D map was measured with
Raman spectroscopy obtaining information on the drug distribution [134].
The drug distribution in microcontainers after loading the drug using
scCO2 impregnation was investigated in Paper II. A line was selected on top
of the microcontainer and a spectrum at each point of that line was obtained
at different depths (Figure 5.6a). These analyses were performed using DXR
Raman microscope (Thermo Fisher Scientific, Inc., Waltham, USA) with a
signal collection time of 10 s and the signal was averaged two times, using a
50 µm confocal pinhole. All Raman spectra were recorded using a laser with
a wavelength of 780 nm, power of 20 mW and a 50x objective lens. The
results are shown in Figure 5.6b. The map shows the high intensity of a
selected peak in red (1000 cm-1). The selected wavenumber, corresponding
to a characteristic peak of ketoprofen. This map shows the distribution of
ketoprofen in the microcontainers after being loaded with scCO2. A similar
map was obtained selecting a wavenumber characteristic for PVP. These
results showed that it was not possible to measure deeper than 50 µm as
PVP was also present below according to the X-ray µCT and SEM analyses.
Figure 5.6: a) Optical image of a microcontainer. The red line represents where
the measurements were taken. A spectrum was collected for each point on the line
at different depths ranging from 0 to 300 µm. b) Results of the measurements: Ra-
man map in which every point represents the intensity of ketoprofen characteristic
peak (1000 cm-1) represented by a color scale (blue to red indicates low to high
intensities).
Since it was not possible to obtain a cross section of a microcontainer
due to low transparency of the sample, a laser (microSTRUCT vario, 3D
Microac AG, Chemnitz, Germany) was used to cut the microcontainers in
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half (Figure 5.7a). The idea was to analyze the cross-section generated by
the cut (Figure 5.7b) to obtain the full cross section of the microcontainer
[134]. The cutting process was successful but the laser burned the filling
materials so it was not possible to detect any material from the analyses of
the samples.
Figure 5.7: Optical images of a microcontainer cut with a laser a) from the top
and b) from the side.
To obtain a 3D distribution of the drug, it was needed to use a custom-
made highly sensitive confocal Raman microscope with a laser power of 30
mW. Due to the high laser power, a Peltier cooling system was added to
control the temperature of the sample during the measurements. Moreover,
a Non-Negative Least Squares (NNLS) analysis was performed to distin-
guish between the different components: Si, SU-8, PVP and ketoprofen or
naproxen. This part of the project was done in collaboration with Dr. Olek-
sii Ilchenko and Roman Splipets. They designed and built the instrument,
measured the samples and analyzed the data.
5.5 Intestinal drug transport investigations
5.5.1 In vitro cell transport studies
As explained in Chapter II, the intestinal barrier plays an important role in
drug absorption. Therefore, it is a common approach to test in vitro whether
the compound has the potential to be transported across the intestinal cells.
To evaluate the amount of compound transported from the lumen to the
portal circulation, a layer of cells modeling the intestinal barrier is grown
on filter supports. This constitutes a cellular barrier which separates two
compartments (Figure 5.8). The formulation that needs to be tested is
placed on the apical side (the “lumen” side) and samples are taken from
both sides over time to evaluate if it is transported to the basolateral side
(Figure 5.8).
The most common cell line, which was also used for these studies, is the
Caco-2 (Cancer Coli-2 or HTB-37). It was established from a human colorec-
tal adenocarcinoma. These cells, when differentiated, express functional and
morphological properties characteristic of the intestinal enterocytes such as
5.5. Intestinal drug transport investigations 43
Figure 5.8: Cell monolayers on filter support used for transepithelial transport
studies, e.g. from the apical to the basolateral side.
being polarized and acquiring the typical apical brush border with microvilli
(Figure 5.9). Moreover, they express enzyme activities typical of enterocytes
and they present tight junctions between adjacent cells [135, 136]. The cor-
relation with the in vivo situation is particularly high if the compounds are
transported by passive paracellular transport mechanisms [137, 138, 139].
Figure 5.9: Schematic representation of the differentiation of Caco-2 cells on
a filter support. When the Caco-2 cells reach confluence (middle) they start to
differentiate spontaneously, and after a period of around 21 days they will appear
with dense microvilli on the apical side typical of small intestinal enterocytes (right)
[136].
One of the main drawbacks of Caco-2 cells is that, being a simple model,
the diverse functions of the intestinal epithelium are not all represented.
Therefore, the addition of different epithelial cell types in an in vitro model
will better reflect the properties of the intestinal barrier. In Chapter 2,
the mucus layer was described as an additional important factor acting as a
barrier to the absorption of some compounds. HT29-MTX cells differentiate
into mature goblet cells which secrete mucins on the apical side. For this
reason, the co-culture of Caco-2/HT29-MTX cell monolayers is quite com-
mon since their combination makes a good model of the two most numerous
cells in the epithelium: enterocytes and goblet cells [140]. In particular,
this combination allows to study how the presence of a mucus layer affects
the permeability of the tested compound in comparison to its permeability
across the Caco-2 cell model.
In Paper IV, both models have been used positioning the microcontainer
chip onto the cell monolayers having the coating layers in contact with the
cells (Figure 5.10). The coated microcontainers filled with the model pro-
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tein lysozyme were tested to evaluate the protein transport across Caco-2
and Caco-2/HT29-MTX cell monolayers. The samples taken during these
experiments were analyzes with HPLC, as described above.
Figure 5.10: Schematic representation of the a) Caco-2 cell monolayer and b)
Caco-2/HT29-MTX cell monolayer with a microcontainer chip on top. The zoom
areas represent microcontainers loaded with lysozyme+C10 and coated with two lay-
ers on top of the cells.
5.5.2 Ex vivo transport studies
Even the combination of two cells type does not represent the multicellular
environment of the intestinal barrier. The transport of compounds across
the intestinal wall can be facilitated by other cell types and therefore, using
ex vivo intestinal tissue segments represents a better model for the in vivo
situation [141, 142]. The possibility of using human tissue is usually quite
limited, consequently, porcine intestinal tissue is commonly used as alterna-
tive. This tissue showed high similarity with that of humans [141, 142].
A side-by-side diffusion chamber called Ussing chamber is used to in-
vestigate intestinal drug transport through excised tissue. This system is
composed by two compartments (as in the cell transport studies) represent-
ing the apical and basolateral sides (Figure 5.11). Each side has a separate
air/gas inlet for the circulation system. The intestinal tissue segment is
mounted in vertical position between the compartments. Before mount-
ing it, the muscle layers need to be removed from the tissue (stripping) to
minimize the influence of the intrinsic neuromuscular system [143]. The
compartments are then filled with buffer at 37 °C. The formulation that
needs to be tested is placed in the apical side and samples are taken over
time from apical and basolateral compartments.
At the end of the experiment, the tissue integrity is assessed using ra-
dioactive labelled compound as paracellular markers for passage through the
tissue. One of the most common markers is D-[1-14C]-mannitol since manni-
tol is a small hydrophilic molecule with very low cell membrane permeability.
A liquid scintillation counting measures the radiolabelled molecules dissolved
in an organic compound able to absorb radiant energy (scintillator). Since
the energy is absorbed, excited atoms rapidly return to the ground state
releasing photons. The concentration of the radioactive labelled molecule
can be translated from the number of emitted photons.
In Paper IV, the functionalized microcontainers filled with the model
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Figure 5.11: Schematic representation of a Ussing chamber system. The zommed
area represents one coated microcontainer loaded with lysozyme+C10 on the tissue.
In the upper part of the figure, the slide with the intestinal tissue with randomly
placed microcontainers on top is represented.
protein lysozyme were placed on the tissue before inserting it in the chamber
to evaluate the transport of lysozyme through the intestinal tissue (Figure
5.11). The samples were analyzed with HPLC.
5.6 Mucoadhesion evaluation
As introduced in the previous chapter, in Paper IV the microcontainers
have been tested for oral delivery of the model protein lysozyme. For this
reason, they have been functionalized by applying polymeric coatings on top
and, therefore, it was necessary to verify if the mucoadhesive layers made a
difference.
Numerous methods have been proposed to assess the mucoadhesive prop-
erties of formulations. These methods can be based on mechanical force
determination or on particle interactions [144]. The method used in this
project is rather simple; the intestinal tissue is placed on a support and
when the mucoadhesive formulation is distributed on the tissue, a pump
can be activated to obtain a flow of the desired buffer on the tissue to mimic
the flow in the intestine [145]. In contrast to what has been found in liter-
ature, the system used to test microcontainers in Paper IV was closed in a
box in which temperature and humidity could be controlled to mimic the
physiological conditions (Figure 5.12a). This technique allows to measure
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how the microcontainers interact with the tissue. In the experiments pre-
sented in Paper IV, a known quantity of microcontainers was placed on the
tissue and a peristaltic pump was activated obtaining a PBS flow on the
tissue (Figure 5.12b). At the end of the experiment, the tissue was left to
dry for 24 hours in order to be able to count the number of microcontainers
that adhered (Figure 5.12c).
Figure 5.12: Picture of a) the mucoadhesion setup, b) tissue with the peristaltic
flow and c) dry tissue with microcontainers that adhered showing mucoadhesive
properties.
Chapter 6
Conclusions and future
perspectives
The first aim of this project was to compare and characterize loading tech-
niques for microfabricated devices for oral drug delivery such as microcon-
tainers.
Two loading techniques for microcontainers were compared (Paper I):
i) hot punching of a PCL film coupled with loading of ketoprofen using
scCO2 and ii) hot punching of a PCL + ketoprofen film. The drug loading
techniques were evaluated by means of in vitro release studies, profilometry,
SEM and X-ray µCT. XRPD and Raman spectroscopy showed no differ-
ences in the solid state form of ketoprofen, resulting in an amorphous form
for both loading techniques. Instead, a pronounced difference between the
two loading techniques was exhibited, due to a difference in the release ki-
netics. This observation highlighted how the choice of the loading technique
is important if a certain release is desired.
Since the scCO2 technique showed a very fast release despite the low
solubility of the chosen excipient (PCL), it was necessary to understand the
spatial distribution of the drug after the loading using this technique (Paper
II). Three different sizes of microcontainers were fabricated to compare if
the area exposed to scCO2 was affecting the distribution of the API loaded
into the polymer matrix. A custom-made Raman microscope allowed to
obtain volumetric Raman maps of an entire microcontainer filled with PVP
and scCO2-impregnated with either naproxen or ketoprofen. For all micro-
container sizes, the drugs were only detected in the top layer of the polymer
matrix, explaining the fast release obtained in the in vitro studies. Using
XRPD and Raman spectroscopy, the solid state form of the drugs was eval-
uated, showing how ketoprofen was amorphous in all microcontainer sizes,
while naproxen was not crystalline.
After comparing and characterizing the loading techniques, microcon-
tainers were tested in vivo as an oral drug delivery system for the poorly
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water soluble model drug ketoprofen (Paper III). This study showed 180%
improvement in the relative oral bioavailablity compared to a control pre-
pared with the same materials as the microcontainer formulation. Before
the in vivo studies, all the preparation steps were characterized using SEM,
X-ray µCT, in vitro release studies and Raman spectroscopy.
The second aim of the project was the exploration of the possible use
of microcontainers as an oral delivery system for proteins. Therefore, the
microcontainers were functionalized to further enhance their features for
this purpose (Paper IV). The functionalization was made by applying two
polymeric layers on top of the microcontainers loaded with the model pro-
tein lysozyme and the permeation enhancer C10. The functionalized mi-
crocontainers were characterized in vitro for morphology, drug release and
mucoadhesive properties. These were coupled with in vitro and ex vivo stud-
ies using Caco-2 and Caco-2/HT29-MTX-E12 cell monolayers, and porcine
intestinal tissue.
From all the results above, in this project, it was shown that: i) the
loading technique influences, among others, the release profile of the drug,
ii) it is possible to use a custom-made Raman microscope to obtain a 3D
map of an entire microcontainer and evaluate the distribution of the loaded
drug in a polymer matrix, iii) microcontainers enhance the oral delivery of
a poorly soluble model drug in vivo and iv) it is possible to functionalize
the microcontainers to enhance mucoadhesiveness and tune the release in
case of protein delivery.
Starting from the results obtained in this project, there are still many
directions to explore in order to fully understand the behavior of microcon-
tainer as oral drug delivery system. In particular, the delivery of prodrugs
using microcontainers as a delivery system showed preliminary positive re-
sults. In the future, the experimental setup needs to be improved and even-
tually followed by in vivo rat study. For example, this will allow to assess
if the microcontainers can limit the prodrug transformation in the GI fluids
and reach the intestinal barrier for an improved transport of the prodrug to
its target.
Regarding delivering probiotics, microcontainers have the potential to
ensure a better establishment and colonization of the microorganisms com-
pared to the commercially available technologies available today. In this
regard, the microcontainer fabrication can be adjusted to obtain two cavi-
ties: one for the probiotics and the other one for prebiotics or antibiotics. If
the target area for probiotics is the colon, another possible aspect that needs
to be further addressed is the microcontainer coating. As discussed in the
thesis, the pH values and transit times in the GI tract are affected from dif-
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ferent factors, so the coating characterization will be of utmost importance
for the release in the colon.
As a final remark, there is a need for understanding if amorphous in-
domethacin is stable in different shapes. This will allow to understand if
the stability depends only on the fact that the API is confined or if it is a
combination of rounded shape and confinement.
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A B S T R A C T
This work explores the potential of polymeric micrometer sized devices (microcontainers) as oral drug delivery
systems (DDS). Arrays of detachable microcontainers (D-MCs) were fabricated on a sacriﬁcial layer to improve
the handling and facilitate the collection of individual D-MCs. A model drug, ketoprofen, was loaded into the
microcontainers using supercritical CO2 impregnation, followed by deposition of an enteric coating to protect
the drug from the harsh gastric environment and to provide a fast release in the intestine. In vitro, in vivo and ex
vivo studies were performed to assess the viability of the D-MCs as oral DDS. D-MCs improved the relative oral
bioavailability by 180% within 4 h, and increased the absorption rate by 2.4 times compared to the control. This
work represents a signiﬁcant step forward in the translation of these devices from laboratory to clinic.
1. Introduction
Oral administration of drugs is preferred by patients [1] due to its
inherently reduced invasiveness compared to injections and minimal
need for trained personnel [2,3]. Moreover, the eﬀective healthcare
costs can be diminished avoiding the usage of drugs administered by
injections [4,5].
Following oral administration, drug absorption will occur in the
gastro-intestinal (GI) tract; primarily in the small intestine due to ahigh
surface area provided by the presence of villi and microvilli [6,7].
When delivering drugs through the GI tract, care needs to be taken due
to the presence of enzymes and a low gastric pH (1–3.5 in fasted state
and 3–6 in fed state) [8]. Both of these can have a negative impact on
the administered drug, thereby limiting the eﬀect of the oral formula-
tion.
Traditional oral dosage forms, such as tablets or capsules, can be
designed to target the intestine. Enteric coatings can be used to protect
the dosage form during transit of the stomach and facilitate the delivery
of the drug to the intestinal epithelium for systemic absorption [9,10].
Tablets, capsules as well as micro- and nanoparticulate systems (i.e.
vesicles, polymeric particles and dendrimers) [11–13], manifest an
omni-directional release of the drug in the intestinal lumen. Omni-di-
rectional release entails an inevitable loss of the drug in the lumen and
therefore a reduction of the drug absorbed into the systemic circulation.
Recent and promising approaches focus on reservoir-based micro-
devices serving as drug carriers, potentially bringing the drug to the
desired place of absorption by unidirectional release from the device.
An example of such microdevices is microcontainers. Here a polymeric
cylinder is situated on a ﬂat surface, deﬁning a container structure with
a cavity in the micrometer size [14,15]. Microcontainers provide uni-
directional drug release due to their design and a protection of the drug
formulation from the acidic environment of the stomach. Previously,
they have been suggested as a promising oral drug delivery system, for
instance maintaining indomethacin in its amorphous state [16,17] and
being suitable for the conﬁnement of spray dried lipid nanoparticles
[18]. Furthermore, microcontainers have shown to improve the oral
bioavailability of an amorphous salt of furosemide (a class IV drug in
the Biopharmaceutics Classiﬁcation System (BCS)), compared to the
same drug loaded into a capsule. It was speculated by the authors that
this could be due to the protection of the drug during the passage
through the stomach and because of an engulfment of the micro-
containers in the intestinal mucus, resulting in a prolonged absorption
period [19]. Chirra et al. have illustrated the beneﬁcial eﬀect of using
microdevices to improve the relative oral bioavailability of the BCS
class III drug, acyclovir compared to a solution of the same drug [20].
Moreover, Fox et al. have shown that nanostraw membranes (porous
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nanostructured delivery substrates) increase adhesion to the mucus and
facilitate the drug loading via diﬀusion [21]. So far, the presented
works have only covered part of a device development and/or char-
acterization and, in most cases, not reporting on in vivo studies and not
characterizing the devices and drugs after individual processing steps.
For example, we have previously reported on drug loading of polymer
ﬁlled microcontainers using supercritical carbon dioxide (scCO2) [22].
However, these containers were not detachable and thus, never used in
animal studies. Likewise, we have reported on microcontainers loaded
with powder of furosemide [19] where the ﬁlled containers were me-
chanically removed from the carrier substrate introducing a risk of
damaging the containers.
Here we present, for the ﬁrst time, the complete process of devel-
oping and characterizing a microcontainer-based oral delivery system.
The aim of this work was to translate detachable microcontainers (D-
MCs) ﬁlled with drug and sealed with a lid, from the concept to the ﬁnal
oral DDS suitable for in vivo and ex vivo studies. For this purpose, D-MCs
have been fabricated on a sacriﬁcial layer, improving handling and
facilitating detachment and collection of the individual ﬁlled and
coated D-MCs. D-MCs were loaded with the BCS class II model drug
ketoprofen utilizing scCO2 followed by an enteric coating to prevent
release of the formulation during handling, detachment and transit
through the stomach. The loaded and coated D-MCs were investigated
in vitro to assess the functionality of the enteric lid, and in vivo and ex
vivo, to evaluate the potential of microcontainers as an oral DDS.
2. Materials and methods
2.1. Fabrication of detachable microcontainers (D-MCs)
Silicon (Si) wafers (4-in. b100N n-type) were supplied by Okmetic
(Vantaa, Finland). SU-8 2075 and SU-8 developer were purchased from
Microresist Technology GmbH (Berlin, Germany). Polyacrylic acid
35 wt% aqueous solution (PAA, Mw 100,000) was purchased from
Sigma Aldrich (St. Louis, USA) and neutralized with NaOH. A 15 μm
thick ﬁlm of PAA was spin coated on a Si wafer and dried at 80 °C for
10 min. The PAA ﬁlm served as a water soluble release layer after
completed detachable microcontainers (D-MCs) fabrication [23]. D-
MCs were fabricated with epoxy-based photoresist SU-8 using a pro-
cedure similar to the one described earlier [15,16]. After fabrication,
the wafers were cut into square chips containing 625 D-MCs using a
laser (microSTRUCT vario, 3D Microac AG, Chemnitz, Germany). The
dimensions of the D-MCs were measured using an Alpha-Step IQ Stylus
Proﬁlometer (KLA-Tencor Corporation, Milpitas, USA) and optical mi-
croscopy.
2.2. Loading of drug formulation into the microcontainers
D-MCs sitting on a Si chip were manually loaded with poly-
vinylpyrrolidone (PVP) (Mw= 10,000, Sigma Aldrich, St. Louis, USA)
blowing away the excess in between the D-MCs using an air gun in a
similar setup as described previously [18,19]. The chips were weighted
before and after and placed within a supercritical CO2 chamber (3 chips
at a time, see Fig. 1), together with 14.2 ± 0.1 mg (n = 15, SD) of
ketoprofen powder (≥98% racemate, Sigma Aldrich, St. Louis, USA).
The impregnation of the polymer was conducted by bringing CO2 over
its supercritical state at 100 bar and 40 °C, keeping it under stirring for
1 h. During this process ketoprofen solubilizes in supercritical CO2 and
diﬀuses into the polymer matrix. The pressurization and depressuriza-
tion rate were 3.9 bar/min and 2.5 bar/min, respectively.
2.3. Enteric coating deposition
A pH sensitive polymer, Eudragit® L100 (Evonik, Darmstad,
Germany) was employed for the enteric coating on the cavity of the D-
MCs. A solution of 2% w/v Eudragit® L100 and 5% w/w in relation to
the polymer of dibutyl sebacate (Sigma Aldrich, St. Louis, USA) was
dissolved in isopropanol (Sigma Aldrich, St. Louis, USA).
The solution was sprayed over a chip of drug-loaded micro-
containers using an ultrasonic spray coater equipped with an accumist
nozzle operating at 120 kHz (Sono-Tek, USA). During the procedure,
the ﬂow rate was kept at 0.1 mL/min, together with a 1.5 W generator
power. The shaping air was set to 0.02 bar, and the speed of the nozzle
was maintained at 5 mm/s, keeping a distance between the tip and the
sample of 6.5 cm. The nozzle of the spray coater was positioned above
the chip containing loaded D-MCs, following a path in the x-y axis to
cover an area deﬁned by the corners of the chip, previously identiﬁed
using an integrated camera. Each chip was coated with two alternating
wavy line spray paths having an oﬀset of 2 mm, resulting in a total of
100 passages. The chips were kept at 40 °C during the spray coating
process.
2.4. Morphology characterization
X-ray micro computed tomography (X-ray μCT, Zeiss Xradia 410
versa, Pleasanton, USA) was applied to assess the ﬁlling level of the
ketoprofen:PVP formulation into the D-MCs and the coating mor-
phology on the cavity of the D-MCs. The 3D tomographic reconstruction
was done with the software, provided with the system, based on a FDK
algorithm [24]. The chip with D-MCs was investigated using a high
voltage of 60 kV and having an eﬀective pixel size of 19.33 μm, taking
1601 projection images. For examining smaller parts of the chip with a
higher resolution 60 kV as high voltage and an eﬀective pixel size of
3.02 μm with 3201 projection images was utilized. Three areas from
each sample were analyzed to obtain a more representative image of
the whole chip.
Capsules ﬁlled with D-MCs were scanned to assess the eﬀect of the
collection of the D-MCs after their detachment, to assess if they were
separated one to each other and if the coating was still intact. For this
purpose, scans were recorded with a voltage of 40 kV with a pixel size
of either 10.23 μm or 3.36 μm, taking 1601 projection images.
The quality of both the loading and the coating of the D-MCs was
investigated using a Zeiss Supra 40VP Field Emission Scanning Electron
Microscope (SEM, Carl Zeiss Microscopy GmbH, Jena, Germany). The
samples were placed over metallic holders and tilted to 30° prior the
analyses, both low and high vacuum modes were used with a variable
energy between 4 and 8 keV.
The coating thickness of Eudragit® L100 was measured by contact
proﬁlometry (Alpha-Step IQ Stylus Proﬁlometer, KLA-Tencor
Corporation, Milpitas, USA). Eudragit® L100 ﬁlms were sprayed on a
SU-8 covered ﬂat silicon chip as described in the above section ‘Enteric
Fig. 1. Schematic representation of the supercritical CO2 impregnation process. Within
the chamber the loading of three D-MCs chips due to the solubilization of ketoprofen in
the supercritical CO2 is depicted. On the right, a zoom in of one D-MC during the loading
process is represented.
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coating deposition’. The proﬁles were measured using a 15.6 mg tip
force with a scan speed of 20 μm/s and a sampling rate of 50 Hz.
2.5. Solid state characterization of ketoprofen
X-Ray powder diﬀraction (XRPD) was used to determine the solid
state form of ketoprofen in the D-MCs and of the controls. An X'Pert
PRO X-ray diﬀractometer (PANalytical, Almelo, The Netherlands, MPD
PW3040/60 XRD; Cu KR anode, λ= 1.541 Å, 45 kV, 40 mA) was uti-
lized. A starting angle of 5° 2θ and an end angle of 30° 2θ were em-
ployed for the scans with a scan speed of 0.67335° 2θ/min and a step
size of 0.0262606° 2θ. Data were collected using X'Pert Data Collector
software (PANalytical B.V.). The diﬀractogram of loaded and coated D-
MCs was compared to that of crystalline ketoprofen, coated D-MCs
loaded with crystalline ketoprofen and D-MCs loaded with 1:4 crys-
talline ketoprofen:PVP. The diﬀractograms of D-MCs on the PAA layer,
PVP and Eudragit® L100 were also investigated for comparison (data
not shown). Moreover, XRPD was used to verify the amorphous form of
ketoprofen in the control samples for the in vivo studies (described in
the ‘Capsules preparation’ section).
In addition, the solid state form of ketoprofen impregnated into the
D-MCs and of control formulations was assessed by means of Raman
spectroscopy using a DXR Raman microscope (Thermo Fisher Scientiﬁc,
Inc., Waltham, USA). The microscope was coupled to a single grating
spectrometer with 5 cm−1 FWHM spectral resolution and± 2 cm−1
wavenumber accuracy. All spectra were collected using a laser with a
wavelength of 780 nm, with a 50× objective and an estimated laser
spot of 3.6 μm diameter. A 50 μm slit was utilized when analyzing bulk
powder, whereas a 25 μm pinhole was deployed to analyze the keto-
profen inside the microcontainers the laser power was equal to 10 and
20 mW, respectively. The spectra of: i) pure ketoprofen, ii) pure PVP
and iii) microcontainers ﬁlled with PVP and impregnated with keto-
profen were compared.
2.6. Release of ketoprofen from D-MCs
The eﬃcacy of the coating and its resistance after the detachment of
the D-MCs was evaluated determining the release of the impregnated
ketoprofen, both in a Fasted State Simulated Gastric Fluid
(FaSSGF pH 1.65 – Biorelevant®, London, UK) and Fasted State
Simulated Intestinal Fluid (FaSSIF pH 6.5 – Biorelevant®, London, UK).
Impregnated chips either coated or uncoated were individually im-
mersed in 2 mL of deionized water (pH 3.25) to allow the solubilization
of the PAA layer (avoiding the coating to dissolve) and hence, the de-
tachment of the D-MCs. Suspended D-MCs were transferred into dialysis
bags (MW cut oﬀ: 14,000) and placed in 20 mL of FaSSGF in an orbital
shaking water bath at 37 °C, 150 rpm (Grant Instrument Ltd., model
OLS26, Cambridge, UK) for 2 h. Afterwards, the bags were removed,
rinsed with FaSSIF and placed in 20 mL of fresh FaSSIF at 37 °C,
150 rpm for 6 h. 20 μL were collected at 0, 5, 10, 20, 40, 60, 120 min
during the release in FaSSGF and after 1, 2, 5, 10, 20, 40, 60, 120, 240
and 360 min during the release in FaSSIF. Samples were analyzed using
the UV–Vis spectrophotometer (NanoDrop 2000c, Thermo Fisher
Scientiﬁc Inc., UK) at 258 nm. The amount of ketoprofen loaded in the
D-MCs chips was also investigated as described in the section ‘In vitro
release of ketoprofen from coated D-MCs’. The release curves were
performed at least in triplicates (n = 3 for the coated and n = 6 for the
uncoated D-MCs).
2.7. Capsules preparation
Three chips of D-MCs were impregnated together and coated in-
dividually as described above. The solubilization of the sacriﬁcial layer
and the subsequent detachment from the Si chip were obtained soaking
the chips into 5 mL of deionized water (pH 3.25). After 5 min, the water
was removed and the D-MCs were dried at 37 °C for 15 min. Gelatin
capsules (Torpac® size 9, Fairﬁeld, USA) were ﬁlled with individual D-
MCs (258 ± 31 D-MCs per capsule, as visible in Fig. S5 in the
Supplementary information) and weighted before and after ﬁlling. The
concentration of ketoprofen in the capsules was assessed in vitro by
placing 14 capsules in 20 mL of phosphate buﬀered saline (PBS, Sigma
Aldrich, St. Louis, USA) and kept under stirring (150 rpm) at 37 °C for
24 h. Measurements were done through UV–Vis spectroscopy as de-
scribed before at a wavelength of 258 nm.
The preparation for the control for the in vivo study started with a
physical mixture of ketoprofen and PVP powders with the same weight
ratio (1:4) as in the D-MCs. The mixture was prepared by heating it up
to 120 °C on a heating plate gently mixing the two compounds during
the melting of the drug. The heated mixture was immediately quenched
using liquid nitrogen followed by grinding to a ﬁne powder. The
amorphous form of ketoprofen was conﬁrmed using XRPD as previously
described. Gelatin capsules were loaded with 922.4 ± 11.5 μg of the
grinded powder, an amount corresponding to that of the D-MCs for-
mulation. Subsequently, the capsules were coated with a solution of 5%
w/v Eudragit® L100 and 5% w/w dibutyl sebacate in relation to the
polymer in isopropanol. The capsules were coated by dipping half of it
into the coating solution and dried for 15 min before coating the other
half. This procedure was repeated three times for each capsule.
2.8. In vivo and ex vivo studies
All animal care and experimental studies were performed according
to Danish and European laws, guidelines and policies for animal
housing, care and experiments at the University of Copenhagen. The in
vivo experiment was carried out at the Department of Experimental
Medicine, University of Copenhagen and approved by the local in-
stitutional Animal Welfare Committee under the license number 2015-
15-0201-00454. The ex vivo study was performed at the Department of
Pharmacy, University of Copenhagen under the license number 2016-
15-0201-00892. Both studies were carried out in compliance with the
Danish laws regulating experiments on animals and EC Directive 2010/
63/EU.
Male Sprague-Dawley rats were housed in pairs in cages to accli-
matize for a period of one week with a light/dark period of 12/12 h and
a temperature of 22 °C with a relative humidity of 55 ± 10%. During
this period, the rats had free access to standard pellets and water.
For the in vivo study the rats with a weight ranging from 373 to
436 g were randomly divided into two groups. One group was dosed
with capsules loaded with D-MCs (n = 11), the second group was dosed
with capsules containing the control formulation (n = 6). Both types of
capsules were given using a polyurethane feeding tube (Instech
Laboratories Inc., Plymouth Meeting, USA), one capsule was dosed per
rat. The rats were fastened for 1 h before and after the dosing, and for
the rest of period they had free access to water and standard pellets.
Blood (200 μL) was sampled through the lateral tail vein at 15, 30, 45,
60, 75, 90, 120 min, 4, 6, 8 and 24 h post dosing and collected in
ethylenediaminetetraacetic acid tripotassium salt dihydrate (EDTA,
Sigma-Aldrich, St. Louis, USA) coated tubes. Plasma was obtained by
immediately spinning the blood samples at 1500 g for 10 min. Plasma
was stored at −20 °C until further analyses.
For the ex vivo study, two male Sprague–Dawley rats weighting 316
and 319 g were used and were fasted 1 h prior to dosing.
Capsules ﬁlled with D-MCs (see the section ‘Capsules preparation’)
were administered to the rats by oral gavage as described previously.
After 90 min post-dosing, the rats were sacriﬁced, and opened at the
linea alba for retrieving the stomach and small intestine. These were
immediately cut open and examined for localizing the D-MCs using a
stereo microscope (SteReo Discovery V8, Carl Zeiss MicroImaging
GmbH, Jena, Germany).
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2.9. High Pressure Liquid Chromatography (HPLC) analysis of plasma
samples
HPLC analyses were performed using a Dionex Ultimate 3000 Pump
equipped with a Dionex ASI-100 Automated Sample Injector and with a
UV-VIS lamp.
Ketoprofen was extracted from the plasma samples using a method
described elsewhere [25] with minor modiﬁcations. Brieﬂy, methanol
was added in a 3:1 v/v ratio to the plasma and, after vortexing the
mixtures, the samples were centrifuged at 15,000 g for 6 min and the
supernatants were transferred into HPLC vials.
The HPLC was run in isocratic mode using a method already de-
scribed in literature with slight modiﬁcations [25]. The mobile phases
constituted of (A): deionized water with 1% v/v triﬂuoroacetate (Sigma
Aldrich, St. Louis, USA) and (B): 100% acetonitrile (Sigma Aldrich, St.
Louis, USA). The ratio of the mobile phase A:B was equal to 45:55 v/v.
Samples were run over a Kinetex 5.0 μm XB-C18 100 Å, 100 × 4.6 mm
column (Phenomenex ApS, Nordic Region, Værløse, Denmark) at 22 °C.
The injected volume was 40 μL with a ﬂow rate of 1 mL/min and a total
run time per sample of 10 min. The absorbance was measured at
258 nm.
2.10. Statistics
For the in vivo studies, all results were normalized for the averages
of rat mass and of the ketoprofen dosed.
To calculate the standard error for the area under the curve (AUC,
Table 1), the standard error of the mean of correlated variables is used
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where Ai is the AUC for region i.
To calculate the average amount of PVP inside a capsule, and the
associated standard error, the following formula is derived. To derive
the formula, it is assumed that the amount of PVP in each D-MCs in the
ﬁlling process are independently distributed.
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where Nc is the total amount of microcontainers per chip, X is the total
amount of PVP measured N times, and Y is the number of micro-
containers contained inside a capsule, measured M times.
The raw data of the in vivo studies can be found in the
Supplementary information (Fig. S4).
Moreover, as the sample sizes are diﬀerent the eﬀect sizes reported
in Table 1 uses the Hedges g eﬀect size deﬁned as g=(M1−M2)/
SDpooled where SDpooled is the weighted standard deviation of the two
groups [26–28].
All of the data are expressed as mean and the usage of standard
deviation (SD) or standard error of the mean (SE) is deﬁned within the
text. Where appropriate, statistical analysis was carried out using
Student t-tests using GraphPad Prism version 6.05. P-values below 5%
(p < 0.05) were considered statistically signiﬁcant.
3. Results
3.1. Fabrication of microcontainers on a sacriﬁcial layer
D-MCs were successfully fabricated in SU-8 on a water soluble layer
of PAA. D-MCs had a height of 304 ± 12 μm (n = 8, SD) and a dia-
meter equal to 329 ± 5 μm (n = 8, SD). The inner reservoir had a
depth of 272 ± 6 μm (n = 8, SD) and a diameter of 188 ± 4 μm
(n = 8, SD) resulting in a container volume of 7.5 ± 0.3 nL (n = 8,
SD). D-MCs were adhering well to the PAA layer not impairing the
handling. D-MCs were arranged in arrays of 25 × 25 devices on
quadratic chips with a side length of 12.8 mm.
Fig. 2. Morphological characterization of drug loaded D-
MCs. (a) and (b): SEM images of D-MCs ﬁrst manually
loaded with PVP and then impregnated with ketoprofen in
supercritical CO2 at 40 °C and 100 bar for 1 h. (c):X-ray μCT
cross-sectional view of the loaded D-MCs.
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3.2. Loading of D-MCs
Every chip with D-MCs was manually ﬁlled with 1.79 ± 0.21 mg
(n = 54 chips, SD) of PVP powder followed by loading ketoprofen into
the polymer matrix using scCO2. All chips underwent the same super-
critical treatment at 40 °C and 100 bar for 1 h. The ﬁlled D-MCs on
chips were visualized using a SEM (Fig. 2a, b). The cross-sectional X-ray
μCT image of the D-MCs loaded with PVP and ketoprofen is shown in
Fig. 2c.
3.3. Enteric coating deposition onto drug-loaded D-MCs
The spray coated gastro-resistant lid of Eudragit® L100 was, in-
itially, characterized using contact proﬁlometry to deﬁne the coating
thickness on two chips. This resulted in thicknesses of 123.0 ± 1.9 and
118.7 ± 3.3 μm (SD describes the roughness of the surface of the
coating). X-Ray μCT and SEM were utilized to assess the morphology of
the coatings after their deposition on the cavity of the D-MCs. The
coatings were homogenous (Fig. 3a, b) and well distinguishable from
the impregnated PVP and ketoprofen (Fig. 3c).
3.4. In vitro release of ketoprofen from coated D-MCs
The detachment of the drug-loaded and coated D-MCs from the PAA
layer was accomplished by soaking chips in deionized water at pH 3.25
for about 5 min.
The release of ketoprofen was evaluated in human FaSSGF for
120 min (simulating the residence time in the stomach) followed by
investigation of the drug release in human FaSSIF for 360 min (simu-
lating the transit time of the small intestine). After 120 min in FaSSGF,
56 ± 14% of the loaded ketoprofen from uncoated D-MCs was re-
leased compared to 16 ± 3% from the coated D-MCs (Fig. 4). Upon
changing to FaSSIF, a burst release with a signiﬁcant immediate con-
centration diﬀerence was noticed for the coated microcontainers (p-
value = 0.0022). After 6 h in FaSSIF, 100% of the loaded ketoprofen
was released from both the coated and uncoated D-MCs. The release
proﬁle of ketoprofen for the uncoated D-MCs did not present a burst
release, but instead followed a ﬁrst order kinetic. Consequently, sta-
tistical signiﬁcance (p-value = 0.002) was noticeable for the release of
ketoprofen after 2 h between coated and uncoated D-MCs. The total
amount of ketoprofen loaded into a single chip with 625 D-MCs was
424 ± 10 μg (n = 14, SE) corresponding to a weight ratio of
Fig. 3. Morphological characterization of loaded and
coated D-MCs. (a) and (b):SEM images of D-MCs coated
with Eudragit® L100 onto the cavity of the drug-loaded D-
MCs. (c): X-ray μCT cross-sectional view of the drug-loaded
and coated D-MCs.
Fig. 4. In vitro cumulative release of ketoprofen. Coated (red line) and uncoated (black
line) D-MCs. For the ﬁrst 120 min, the chips were placed in FaSSGF and subsequently in
FaSSIF for 360 min. Each release curve is calculated as mean ± standard deviation
(n = 6 for the uncoated D-MCs, n = 3 for the coated D-MCs). For the individual proﬁles
refer to Fig. S3 in the Supplementary information. (For interpretation of the references to
colour in this ﬁgure legend, the reader is referred to the web version of this article.)
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ketoprofen to PVP of approximately 1:4 (see the ‘Formulation pre-
paration for in vivo and ex vivo studies’ section). The total amount of
ketoprofen loaded into the coated and uncoated D-MCs were seen to be
very similar. No signiﬁcant diﬀerence was found (p-value = 0.2542).
3.5. Solid state characterization of ketoprofen in D-MCs
The solid state form of ketoprofen in the D-MCs both after scCO2
impregnation and after additional enteric coating deposition was
evaluated by means of XRPD. By comparing the diﬀractograms
(Fig. 5a), it was found that the distinct peaks of crystalline ketoprofen
were not visible in the ﬁnal scCO2 impregnated and coated micro-
containers. This, together with the typical scattering halo (Fig. 5a, red),
indicated the maintenance of ketoprofen in its amorphous form within
the D-MCs. The two controls (coated D-MCs loaded with crystalline
ketoprofen and D-MCs with a crystalline ketoprofen:PVP mixture in the
ratio 1:4) demonstrated that it was possible to measure through the
coating and to detect crystalline ketoprofen in the D-MCs in the same
quantity as seen in the scCO2 impregnated and coated microcontainers
(Fig. 5a, blue and green).
It is worth mentioning that the melted and quenched mixture of
ketoprofen:PVP 1:4 (used as control for the in vivo studies) was also
found to be amorphous in the XRPD diﬀractograms (see in
Supplementary information Fig. S1).
The XRPD results were corroborated by Raman spectroscopy
comparing the spectra of pure crystalline ketoprofen, pure PVP and
microcontainers ﬁlled with PVP and impregnated with ketoprofen
(Fig. 5b). As noticeable from the Raman spectra, the characteristic vi-
brational patterns of ketoprofen were also visible in the impregnated D-
MCs. Brieﬂy, the intensity of the peak at 1657 cm−1, which is attrib-
uted to the vibrational stretch of the carbonyl ν(C]O), decreased
compared to that of crystalline ketoprofen. Moreover, the broadening of
the band around 1198 cm−1 (CH ring plane bending) together with the
lowering of the peak intensities between 1500 cm−1 and 1100 cm−1,
supported the hypothesis of ketoprofen amorphization due to the im-
pregnation process [29].
3.6. Formulation preparation for in vivo and ex vivo studies
Gelatin capsules were ﬁlled with 258 ± 31 (n = 54, SE) scCO2
loaded and coated D-MCs corresponding to 176 ± 14 μg (n = 14, SE)
of ketoprofen and 741 ± 52 μg (n = 54, SE) of PVP.
X-ray μCT was employed to visualize the microcontainers inside the
capsule. It can be seen that the coating was preserved through all
preparation steps and that the microcontainers were intact and sepa-
rated from each other (Fig. 6).
3.7. In vivo studies
Capsules ﬁlled with D-MCs or with the control formulation were
Fig. 5. Solid state characterization of ketoprofen in D-MCs. (a)
XRPD diﬀractograms of crystalline ketoprofen (black), D-MCs
impregnated with ketoprofen and coated (red), D-MCs loaded
with crystalline ketoprofen and coated (blue) and D-MCs loaded
with 1:4 crystalline ketoprofen:PVP (green). (b) Raman scat-
tering proﬁles of PVP powder (blue), crystalline ketoprofen
(black) and D-MCs impregnated with ketoprofen (red). (For in-
terpretation of the references to colour in this ﬁgure legend, the
reader is referred to the web version of this article.)
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dosed by oral gavage to rats. The measured plasma concentration of
ketoprofen over time is presented in Fig. 7 and key results are sum-
marized in Table 1. The maximum plasma concentrations (Cmax) are
similar for D-MCs and the control. The values were found to be
657 ± 78 ng/mL and 488 ± 105 ng/mL for the formulation with D-
MCs and for the control, respectively (p-value = 0.2191). The AUC
from 0 to 24 h (AUC0-24h) was calculated to be 406 ± 40 min·ng/mL
for the D-MCs formulation and 320 ± 49 min·ng/mL for the control,
thereby, no signiﬁcant diﬀerence was observed between the two groups
(p-value = 0.2041). The relative bioavailability from 0 to 24 h
for ketoprofen in D-MCs compared to the control was found
to be 127 ± 23%. However, statistically relevant diﬀerence
(p-value = 0.0279) was found for the time corresponding to the max-
imum plasma concentration (Tmax) when comparing the two formula-
tions (93 ± 17 min for the D-MC and 212 ± 60 min for the control).
The AUC0-4h for the D-MCs formulation was 99 ± 10 min·ng/mL and
55 ± 18 min·ng/mL for the control resulting in a statistically sig-
niﬁcant diﬀerence between the two groups (p-value = 0.0387). Ac-
cording to this, the oral relative bioavailability from 0 to 4 h was
180 ± 62% for the D-MC formulation compared to the control. The
absorbance rate of ketoprofen (C0 to Cmax) for the rats dosed with D-
MCs was 10 ± 2 ng·min−1·mL−1, which is signiﬁcantly higher than
for the control (4 ± 1 ng·min−1·mL−1) (p-value = 0.0430, Fig. 7, top
right).
3.8. Ex vivo study
In order to understand the mechanism of action of the D-MCs, their
position in the GI tract of the rats at Tmax (90 min) was assessed. No D-
MCs were found in the stomach of the rats at Tmax, whereas many were
found in the mid-jejunum (see Fig. S2 in the Supplementary informa-
tion). This indicates that the enteric coating protected the formulation
until the intestine was reached, where the ketoprofen was released and
absorbed.
4. Discussion
Micro- and nanotechnologies are enabling new possibilities in the
world of oral drug delivery. It is a highly complex and multidisciplinary
ﬁeld with focus on fabrication and on the possibilities to integrate novel
functionalities into drug delivery systems. In vivo studies proving their
actual performances [21,30–32] are, however, not always carried out.
In this work, an oral DDS based on microcontainers has been further
developed compared to previous ones [19,33]. The complete process,
starting from the fabrication of the new D-MCs to the loading and
coating, highlighting the subsequent results from the in vivo and ex vivo
investigations, is presented.
D-MCs were ﬁlled with PVP in a simple and reproducible manner
and scCO2 was used to load the D-MCs with the model drug ketoprofen
with a ﬁnal 1:4 weight ratio of drug to polymer. A single D-MC has a
cavity of 7.5 ± 0.3 nL, 178 times larger compared to other similar DDS
[34], and each one was loaded with 0.68 μg of ketoprofen, which is
considerably more compared to the data presented by Chirra et al.
(1.54 ng) [20]. The amount of ketoprofen in a single D-MC corresponds
to 1.3% w/w of the total weight of the microdevice. The technique of
scCO2 impregnation was preferred over inkjet printing due to the low
spotting reproducibility and low loading capacity of the printing pro-
cess [35,36].
In the loading process, scCO2 acts as a solvent for ketoprofen, but
not for PVP, which only swells [22]. The porosity of PVP increased
during the impregnation allowing ketoprofen to access the D-MCs. CO2,
in its supercritical state, has a density similar to a liquid, whereas the
viscosity and diﬀusivity are closer to the ones of a gas. These features
are exploited during the impregnation process, where ketoprofen is
used in relatively high concentration and diﬀuses easily with the CO2
into the D-MCs.
Fig. 6. X-ray μCT image of a gelatine capsule ﬁlled with loaded and coated D-MCs.
Fig. 7. Plasma concentration of ketoprofen over time. (Red line), capsules with loaded
and coated D-MCs (n = 11, SE). (Black line), control capsules ﬁlled with melted keto-
profen and PVP and coated (n = 6, SE). The inset represents the same proﬁles zoomed in
the ﬁrst 4 h. For the individual proﬁles refer to Fig. S4 in the Supplementary information.
(For interpretation of the references to colour in this ﬁgure legend, the reader is referred
to the web version of this article.)
Table 1
Non-compartmental model of the in vivo study of ketoprofen in D-MCs (n = 11, SE) and for the control formulation (n = 6, SE).
Capsule with loaded and coated D-MCs Coated capsules with 1:4 ketoprofen:PVP amorphous mixture (control) Eﬀect sizeb
Cmax [ng/mL] 657 ± 78 488 ± 105 0.65
Tmax [min] 93 ± 17a 212 ± 60a 1.24
AUC0-4h [min·ng/mL] 99 ± 10a 55 ± 18a 1.16
AUC0-24h [min·ng/mL] 406 ± 40 320 ± 49 0.68
Relative oral bioavailability [%]
0–4 h 180 ± 62%
0–24 h 127 ± 23%
a p-value < 0.05.
b Eﬀect size=(M1−M2)/SDpooled where M1 and M2 are the averages of the two populations andSDpooled is the weighted standard deviation of the two groups.
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During the scCO2 impregnation, a solid state transition of keto-
profen from its crystalline to its amorphous form was obtained.
Ketoprofen is a BCS class II drug meaning that it has a poor solubility in
water. Therefore, its aqueous solubility can be increased by exploiting
the amorphous form [37–40]. The XRPD diﬀractograms and the Raman
spectra (Fig. 5a and b, respectively) suggested that the amorphous form
of ketoprofen was present after impregnation into the D-MCs, con-
ﬁrming previous results [33].
Ketoprofen was kept in its amorphous form for at least 7 days (data
not shown) due to the use of scCO2 and to its aﬃnity with PVP
[29,41,42]. PVP is a water soluble polymer and has unique properties in
prolonging the stability of amorphous forms of drugs, thereby in-
creasing their dissolution rate and solubility [41]. Microcontainers can
additionally stabilize the amorphous form of drugs by spatially con-
ﬁning the drug molecules, leading to an improved physical stability of
the amorphous drugs [16,17].
In order to avoid premature release of ketoprofen, D-MCs were
coated with the gastro-resistant polymer Eudragit® L100. The in vitro
dissolution studies (Fig. 4) conﬁrmed that this polymer successfully
protected the drug during transit through the gastric environment and
dissolved quickly upon arrival in the small intestine (where the pH is
generally above 6) [19,43–46]. Spray coating by an ultrasonic nozzle
was selected as the technology to deposit the coating onto the cavity of
the D-MCs. The morphology of PVP and ketoprofen after impregnation
(Fig. 2) was suitable for the coating deposition as there was still space
for the coating in the top of the cavity of the D-MCs. The deposition of
the lid was simple and straightforward, and has the potential of being
scaled up. D-MCs were detached from the fabrication platform by
soaking them into acidiﬁed water. This approach maintains the in-
tegrity of the gastro-resistant lid (Fig. 6) and it is a gentler and more
controlled procedure than using, for example, mechanical forces. SEM
images and X-ray μCT scans of coated D-MCs showed that after spray
coating no agglomerates of polymer were present between adjacent
microcontainers and that the D-MCs were not attached to each other
after dissolution of the PAA sacriﬁcial layer (Figs. 3 and 6).
The in vitro release of ketoprofen from the D-MCs in gastric and
intestinal simulated media demonstrated the eﬃcacy of the coating.
The immediate release of 16 ± 3% of ketoprofen from the coated D-
MCs in FaSSGF can be explained by the presence of small pores in the
coating (Fig. 3) and/or the possible variation of the polymer mor-
phology (refer to the video in the Supplementary Information for a
more detailed view). For the uncoated D-MCs, 56 ± 14% of ketoprofen
was released in FaSSGF, showing that nothing eﬃciently hindered the
drug release. Coated D-MCs showed a very signiﬁcant burst release
upon changing to FaSSIF due to the dissolution of Eudragit® L100 fol-
lowed by a fast release of ketoprofen, together with dissolution of PVP
(Fig. 4).
In vivo studies are necessary when testing new drug delivery systems
as they provide indications on possible bioavailability improvements
after oral administration compared to a control formulation [47,48].
The control formulation used in these studies was designed to have
the same ratio of ketoprofen:PVP (1:4) and a total amount of drug and
polymer as for the D-MCs formulation to obtain information on the
behavior of the D-MCs. The solid state form of a drug has a large in-
ﬂuence on the dissolution rate, and can therefore, be of great im-
portance for the bioavailability [49]. It was found that ketoprofen in the
D-MCs after scCO2 impregnation was amorphous and consequently, the
ketoprofen in the control formulation was also brought to its amor-
phous form. This was obtained by melting the ketroprofen together
with PVP followed by a fast cooling, which is a common method for
preparing the amorphous form of a drug, as reported by Enfalt et al.
[50].
Compared to the control, the D-MCs formulation did not provide a
higher Cmax. However, a faster Tmax was observed for the D-MCs for-
mulation being roughly 2.3 times faster than the control. This sig-
niﬁcant diﬀerence resulted in a large value for the eﬀect size (Table 1),
in accordance with the classiﬁcation proposed by Choen [28], where
the intervals 0.00–0.20, 0.20–0.50 and 0.50–0.80 correspond to a small,
medium or large eﬀect, respectively. This indicates that D-MCs have a
large eﬀect on the time of absorption. For the ﬁrst 4 h of the plasma
concentration-time proﬁle (Fig. 7), the absorption of ketoprofen was
signiﬁcantly higher than for the control, again resulting in a large eﬀect
size value (Table 1). This diﬀerence resulted in a relative oral bioa-
vailability of 180 ± 62% for the ﬁrst 4 h. In accordance with the dif-
ference between the Tmax values, the absorption rate was signiﬁcantly
higher for the rats administered with D-MCs compared to the control
rats. This supports the conclusion that the D-MCs provided a much
faster absorption of ketoprofen compared to the control. It can be hy-
pothesized that this, to some extent, is caused by a faster gastric emp-
tying of the rats dosed with the D-MCs compared to the control. Indeed,
D-MCs were most likely released from the gelatin capsule in the sto-
mach as no coating was applied to the entire capsule, conversely to the
control formulation. From the plasma concentration curve (Fig. 7), it is
noticeable that after 4 h the two formulations show more similar ki-
netics, and the AUC0-24h is not signiﬁcantly diﬀerent. This is reﬂected in
the relative bioavailability of ketoprofen in the D-MCs formulation
compared to the control being 127 ± 23%. Choi et al. [51] evaluated
the intestinal absorption of a suspension of ketoprofen in rats admin-
istering a 2.3 times higher dosage compared to the one used in the
present study. The authors report a higher Cmax (6.12 ± 1.02 μg/mL)
and a faster Tmax (0.42 ± 0.29 h). Indeed, these results might be at-
tributed to the higher dosage and to the fact that ketoprofen was dosed
in a suspension form, thus, partially pre-solubilized. An important dif-
ference comparing these two studies is the plasma concentration decay
over time. The decrease is slower for the D-MCs, indicating a prolonged
drug release and absorption time. A possible explanation for this might
be provided by the results of our ex vivo study where at the time in
which the Tmax was reached (93 ± 17 min), D-MCs were spread in the
small intestine, and most of them were found in the mid-jejunum em-
bedded deep into the mucus. This pronounced engulfment might indeed
have resulted in a slower release and at the same time allowed pro-
longed absorption of ketoprofen. It has previously been shown in in-
testinal perfusion studies in rats that SU-8 microcontainers have mu-
coadhesive properties showing i.e. a high tendency to be engulfed by
the mucus [19].
5. Conclusions
In this work, we demonstrated that D-MCs are a promising oral drug
delivery system providing a 2.3 times faster Tmax and a 180% increased
AUC0-4h when compared to the control. These features can be of high
importance as it could imply that the administered dose could be re-
duced. The BCS class II model drug ketoprofen was successfully loaded
into D-MCs exploiting the features of scCO2 impregnation maintaining
the API in its amorphous form. Enteric coating was employed to protect
the drug from the stomach environment and to release ketoprofen in
the intestine, as proven by the in vitro study. All preparation steps are
designed to be compatible with each other maintaining ketoprofen in its
amorphous state. In vivo and ex vivo analyses ﬁnally show the potentials
of using D-MCs as an oral drug delivery system.
Supplementary data to this article can be found online at https://
doi.org/10.1016/j.jconrel.2017.10.013.
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1. Introduction
Macromolecules such as proteins are used 
for treatment of diseases such as cancer,[1] 
rheumatoid arthritis,[2] and psoriasis,[3] 
and are mainly administered by injections. 
To increase patient compliance and reduce 
costs for the healthcare system, it would be 
beneficial to deliver proteins and peptides 
via the oral route.[4] Nevertheless, there are 
certain disadvantages, which are related 
to the proteins: instability in the gastro-
intestinal (GI) tract, poor absorption due 
to large size, hydrophilicity and proteolysis 
by enzymes found in the GI tract.[5]
For succeeding with oral delivery of 
proteins, one of the most common strate-
gies is to increase intestinal absorption by 
the use of permeation enhancers.[5] These 
compounds allow the passage of proteins 
across the epithelium by opening the 
tight junctions. Fatty acids, medium chain 
glycerides, and chitosan are among the 
most common examples of permeation 
enhancers.[5] Sodium decanoate (C10) is a 
saturated fatty acid and is well known to 
open tight junctions and can thereby lead 
to a higher transport of large hydrophilic compounds through 
the epithelial cell layer.[6,7]
Moreover, in the last decades, hydrogels, nanoparticles, and 
microparticles have been developed and studied to deliver 
proteins and peptides orally.[8] The major obstacles for these 
delivery systems are the instability, polydispersity, and the con-
trol of the amount of drug that can be loaded.[8] Microfabricated 
devices such as planar reservoirs with a diameter of 200 µm 
and a height of 4–8 µm have been used as carriers for insulin 
showing an enhanced drug permeability in vitro and in vivo.[9] 
The authors highlighted that in these microdevices only about 
50 ng of insulin was loaded and, thus, an excessive number of 
microdevices are needed to be administered per day. Micro-
containers are polymeric cylindrical microdevices with a diam-
eter and height of ≈300 µm having a volume 100 times larger 
than the reservoirs, consequently, they have a higher chance 
of providing a therapeutic dose. The main advantages of the 
devices compared to traditional particulates are that the devices 
1) protect the protein from the GI environment and 2) provide 
unidirectional release that allows the delivery of the protein to 
Oral Protein Delivery
Oral delivery of proteins and peptides is one of the main challenges in phar-
maceutical drug development. Microdevices have the possibility to protect 
the therapeutics until release is desired, avoiding losses by degradation. One 
type of microdevice is polymeric microcontainers. In this study, lysozyme 
is chosen as model protein and loaded into microcontainers with the per-
meation enhancer sodium decanoate (C10). The loaded microcontainers 
are sealed and functionalized by applying polymeric lids onto the cavity of 
the devices. The first lid is poly(lactic-co-glycolic) acid (PLGA) and on top of 
this either polyethylene glycol (PEG) or chitosan is applied (PLGA+PEG or 
PLGA+chitosan, respectively). The functionalization is evaluated in vitro for 
morphology, drug release, and mucoadhesive properties. These are coupled 
with in vitro and ex vivo studies using Caco-2 cells, Caco-2/HT29-MTX-E12 
co-cultures, and porcine intestinal tissue. PLGA+chitosan shows slower 
release compared to PLGA+PEG or only PLGA in buffer and the transport 
of lysozyme across cell cultures is not enhanced compared to the bulk 
powder. Microcontainers coated with chitosan or PEG demonstrate a three 
times stronger adhesion during ex vivo mucoadhesion studies compared to 
samples without coatings. Altogether, functionalized microcontainers with 
mucoadhesive properties and tunable release for oral protein delivery are 
developed and characterized.
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a specific part of the intestine, for example, the small intestine 
where absorption often occurs.[10] Previously, it has been shown 
that small molecules, such as furosemide and ketoprofen in 
microcontainers, coated with pH-sensitive coatings improve the 
relative oral bioavailability of 220% and 180%, respectively com-
pared to controls.[11,12]
For obtaining optimal performance of the devices, the micro-
containers can be functionalized by applying polymeric layers 
as lids on top of the microcontainers. Poly(lactic-co-glycolic) 
acid (PLGA) has been widely used as degradable carrier for 
oral protein delivery.[13,14] Insulin-loaded PLGA nanoparticles 
and microcapsules have been reported to reduce the glucose 
level substantially in diabetic rats.[15,16] In an aqueous environ-
ment, PLGA degrades by hydrolysis to lactic and glycolic acid, 
both easily metabolized by the body.[13] During this process, the 
local environment in, for example, the intestine becomes more 
acidic and, therefore, the solubility of a protein-like insulin can 
be enhanced.[17,18] Mucoadhesive polymers can prolong the 
residence time of the carriers at the site of absorption.[19] Since 
the intestinal mucus turnover time ranges between 30 min and 
few hours, it can be considered slower than the time needed 
for absorption.[20] Chitosan, a mucoadhesive polymer, has been 
used as coating or carrier for micro- and nanoparticles for 
delivery of proteins improving their oral bioavailability.[8] At 
the same time as having mucoadhesive properties, it is also a 
permeation enhancer.[21,22] Polyethylene glycol (PEG) has also 
been widely utilized for oral delivery of proteins.[8] Depending 
on the molecular weight and surface concentration of PEG, it 
has been demonstrated to have either mucoadhesive or mucus 
penetrating properties.[23] Tobío et al. showed that microparti-
cles of the degradable carrier polylactic acid (PLA) coated with 
PEG provided a five times higher oral bioavailability of tetanus 
toxoid than particles without coating. This was explained to be 
due to the mucus penetrating effect of PEG.[24]
In this study, microcontainers loaded with the model pro-
tein lysozyme and C10 were functionalized with polymeric lids 
to be tested in vitro and ex vivo for oral protein delivery. The 
microcontainers were functionalized by applying two layers as 
lids on top of the microcontainers, the first layer was PLGA and 
on top of this, either PEG or chitosan was applied (PLGA+PEG 
or PLGA+chitosan, respectively). The functionalized microcon-
tainers were evaluated in vitro for morphology and drug release 
and, ex vivo for mucoadhesive properties. Furthermore, it was 
assessed if the functionalization of the microcontainers pro-
vided a controlled release and improved lysozyme transport in 
vitro and ex vivo using cell models and porcine intestinal tissue.
2. Results and Discussion
2.1. Functionalization of Microcontainers
The physical powder mixture of lysozyme and C10 (7:3) was 
loaded into the microcontainers (Figure 1a) with an average 
load per chip of 1.98 ± 0.36 mg corresponding to each micro-
container loaded with 3.1 ± 0.6 µg powder mixture (Figure 1b). 
The first functionalization layer was prepared with PLGA 
to help the dissolution of the protein.[13] It was observed 
that the polymer was homogeneously distributed over the 
microcontainers, although, the shape of the lysozyme powder 
was still visible (Figure 1c). On top of the PLGA layer, either a 
layer of PEG (Figure 1d,e) or chitosan (Figure 1f,g) was depos-
ited as penetrating/mucoadhesive polymers. In both cases, after 
applying the second layer, the powder loaded into the microcon-
tainers was completely covered and both coatings were smooth 
(Figure 1e,g). Moreover, considering the X-ray micro computed 
tomography (X-ray µCT) images, it was possible to conclude 
that the two layers were uniformly distributed on the chips 
(Figure 1d,f). The thicknesses of the different coatings with 
only one or two layers were measured using an optical pro-
filometer (Table 1). Chitosan resulted to be the thinnest among 
all the layers which is due to the fact that the chitosan solu-
tion was prepared in a lower concentration compared to PLGA 
and PEG solutions and the spraying parameters were different. 
Moreover, all the measurements showed that the layers were 
homogeneously distributed within the same chip and among 
chips (n = 3, each measured in three points).
2.2. In Vitro Drug Release from Functionalized Microcontainers
The release of lysozyme from the coated microcon-
tainers showed that for the three different coatings (PLGA, 
PLGA+chitosan, and PLGA+PEG), the loaded protein was 
released within 14 h (Figure 2). In the insert of Figure 2, it 
is noticeable that the different coatings resulted in different 
release profiles. The lysozyme released from the microcon-
tainers coated with PLGA+chitosan reached 70.6 ± 6.6% within 
the first 2 h of the experiment. Microcontainers coated with 
only PLGA or PLGA+PEG showed a faster release (92.7 ± 4.6% 
and 93.3 ± 3.7%, respectively) in the first 2 h. Slower release 
from the PLGA coating can be achieved by utilizing PLGA 
standards with either higher molecular weight or larger ratios 
of lactide.[25] In accordance, it has been shown that coatings of 
PLGA+chitosan can induce a sustained release due to the low 
solubility of chitosan at pH 7.4[26,27] as this was also observed 
here for the microcontainers coated with these two polymers. 
In the literature, chitosan nanoparticles loaded with lysozyme 
showed a sustained release due to the swelling of the parti-
cles resulting in 20% of lysozyme released over 3 weeks.[28] 
Chitosan as a lid will also have a tendency to swell due to the 
hydrogel properties of chitosan[29,30] resulting in a slower diffu-
sion process for lysozyme from the microcontainers causing a 
sustained release.
2.3. Ex Vivo Mucoadhesion Studies
Mucoadhesion studies applying intestinal porcine tissue were 
utilized to test if the top layer of the lid (chitosan or PEG) was 
adding a mucoadhesive feature to the microcontainers. Control 
of humidity and temperature (80% relative humidity and 37 °C) 
during the whole experiment allowed for mimicking the physi-
ological environment, avoiding that the tissue dried out during 
the experiments (Figure S1, Supporting Information).[5] The 
number of microcontainers adhering to the tissue after 5 min 
of flow was considered a measure for mucoadhesiveness of the 
microcontainers. Figure 3 shows that in the presence of PEG 
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or chitosan, the percentage of microcontainers adhering to the 
tissue was higher (40.9 ± 5.5% and 35.7 ± 14.1%, respectively) 
than for the microcontainers without coating or with only 
PLGA (13.0 ± 2.3% and 19.3 ± 8.8%, respectively). This means 
that the number of microcontainers coated with either PEG 
or chitosan adhering to the tissue is twofold higher compared 
to the ones only coated with PLGA. If, instead, the number of 
samples coated with PLGA+PEG or PLGA+chitosan is com-
pared with microcontainers without coating, they resulted to 
be three times more mucoadhesive. In particular, the number 
of microcontainers with PLGA+PEG layers that adhered was 
found to be statistically different from the ones having only one 
layer of PLGA (p = 0.0097). The high variability in these experi-
ments can be caused by the random orientation of the micro-
containers and by the use of different pieces of intestinal tissue 
having different mucus thicknesses that can lead to different 
adherence values.[31]
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Figure 1. Scanning electron microscope (SEM) images of a) empty microcontainers, b) microcontainers loaded with lysozyme and C10 (7:3 w/w), and 
c) loaded microcontainers coated with PLGA. X-Ray µCT cross sections and reconstruction of loaded microcontainers coated with PLGA and on top of it 
either d) chitosan or f) PEG. The same samples are illustrated with SEM pictures in e) and g). The scale bars, where not indicated, correspond to 100 µm.
Table 1. Thicknesses of the different coatings either as individual coat-
ings or combined with PLGA.
Coating Thickness [µm]
PLGA 17.1 ± 2.4
PEG 17.0 ± 5.6
PLGA+PEG 32.5 ± 8.0
Chitosan 6.9 ± 1.1
PLGA+chitosan 22.5 ± 3.8
The data represent the mean of three samples measured in three different points 
of a chip (central and sides) ± standard deviation (SD).
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2.4. In Vitro Transport Studies
Transport studies were realized using Caco-2 cell monolayers 
or Caco-2/HT29-MTX-E12 co-culture monolayers as in vitro 
models for absorption through the small intestine. The Caco-2 
cells are intensively used as an in vitro model for the intes-
tinal epithelial barrier to determine the permeability of drug 
compounds through the intestinal barrier.[32] However, Caco-2 
cells are lacking the goblet cells responsible for mucus produc-
tion.[33] In vivo, the mucus layer acts as a physical and chemical 
defense from the luminal content and is important for the pre-
diction of intestinal permeability of compounds, having a great 
importance for the absorption of proteins.[34] For this reason, 
the co-cultivation of Caco-2 and HT29 cell lines are widely used 
since it provides a model constituting the two cell types that 
are most represented in the intestinal epithelium in humans, 
enterocytes, and goblet cells.[35]
The percentage of transported lysozyme versus time 
across the Caco-2 monolayer or the co-culture was calculated. 
The profiles for the lysozyme confined in the microcontainers 
are similar to those of the bulk powder (Figure 4a). Although, 
the microcontainers coated with PLGA+chitosan showed a lag-
time due to a slower transport of lysozyme. The average flux 
(Figure 4b) was calculated for each analyzed sample using 
Equation (1). The microcontainers coated with PLGA and 
PLGA+PEG displayed flux values of 5.3 ± 1.4 × 10−6 nmol 
min−1 cm−2 and 4.9 ± 1.6 × 10−6 nmol min−1 cm−2, respectively, 
hence, there was no significant difference between their flux 
values (p-value 0.0803). These values are also similar to the bulk 
powder of lysozyme and C10. The slower onset in lysozyme 
transport for the chitosan samples (Figure 4a) is likely due 
to slower release of lysozyme. In addition, the slower onset 
resulted in a lower flux compared to all the other samples 
since the flux for microcontainers coated with PLGA+chitosan 
could be calculated only with two values. This delayed transport 
can be due to a delayed release of lysozyme from the micro-
containers as showed in the in vitro studies (Figure 2) in which 
after 2 h, only 70.6 ± 6.6% was released. Moreover, it has previ-
ously been shown that the presence of chitosan in insulin nano-
particles resulted in a slower transport of insulin across Caco-2 
monolayers compared to other formulations.[21] Determination 
of transepithelial electrical resistance (TEER) before and after 
the experiments allowed investigation of the integrity of the cell 
layer. The initial TEER values for all the cells were between 215–
255 Ω cm2 (Figure S2a, Supporting Information). At the end of 
the experiments, all TEER values, except for the blank, dropped 
to 90–120 Ω cm2 (Figure S2a, Supporting Information). This 
complies with previous findings in the literature, observing 
that TEER is reduced across Caco-2 cells following treatment 
with chitosan[36] and especially C10[6,7] as they are both permea-
tion enhancers. Thereby, they are interrupting tight junctions 
between the cells, but it is a reversible process and studies have 
shown that the cells recover within 24 h.[7,36] Microcontainers 
loaded with a protein and C10 (with the same molecular ratio 
as used in this study) have been tested and they did not show 
any cytotoxic effect on Caco-2 monolayers and on Caco-2/HT29-
MTX-E12 co-culture monolayers (data not shown). Neverthe-
less, further characterization would be needed in the future to 
evaluate the cytotoxicity of the coating materials on Caco-2 cell 
monolayers or Caco-2/HT29-MTX-E12 co-culture monolayers. 
The transport of lysozyme from the microcontainers release 
across the Caco-2/HT29-MTX-E12 co-culture was slower than 
the bulk powder (Figure 4c). The calculated lysozyme flux for 
PLGA, PLGA+PEG and PLGA+chitosan coated microcon-
tainer were 6.2 ± 3.5 × 10−6, 2.7 ± 1.2 × 10−6, and 3.9 ± 0.8 × 
10−6 nmol min−1 cm−2, respectively. The flux seems to be highly 
dependent on the presence of a polymeric coating on the 
microcontainers. All coated microcontainer samples resulted 
in a similar low lysozyme flux compared to the relatively high 
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Figure 3. Percentage of microcontainers adhering to intestinal porcine 
tissue after flow for 5 min with 10 mm PBS at pH 7.4. The microcontainers 
were loaded with lysozyme and were either without coating, coated with 
only PLGA, PLGA+PEG, or PLGA+chitosan. The graph represents mean ± 
SEM (n = 3). **, p-value ≤ 0.01.
Figure 2. In vitro release of lysozyme from microcontainers with only 
PLGA, with PLGA+PEG, and with PLGA+chitosan coatings. The release 
was performed on a µ-DISS profiler in 10 mm phosphate buffered saline 
(PBS) at pH 7.4 and 37 °C. The data represent mean + SD, n = 5–6.
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flux seen for the controls (22.8 ± 2.5 × 10−6 nmol min−1 cm−2). 
These results indicate that the coatings interact with the mucus 
present in the Caco-2/HT29-MTX-E12 co-culture resulting 
in a slower transport of lysozyme across the cell monolayers. 
The initial TEER values for Caco-2/HT29-MTX-E12 cell mon-
olayers were at consistent levels in the range of 345–390 Ω cm2 
(Figure S2b, Supporting Information). TEER values dropped for 
all the samples at the end of the experiments (2 h), however 
not significantly for the blank (Figure S2b, Supporting Infor-
mation). The microcontainers with the chitosan layer showed 
its permeation enhancing properties having a lower TEER value 
compared to the other coated with PEG or only PLGA.
The lowering of the TEER values for PLGA+chitosan, in both 
types of monolayers, highly indicated chitosan interaction with 
the cell monolayer. The lysozyme flux for the PLGA+chitosan 
coated microcontainers was observed to be higher across the co-
culture than Caco-2 cell monolayers (p = 0.0101). A reason for 
this could be the presence of mucus and PEG-chitosan’s known 
ability to form hydrogels.[37,38] This could allow slower diffusion 
of lysozyme through the coating in presence of mucus.[5]
2.5. Ex Vivo Transport Studies
Ex vivo transport studies are more representative of the intes-
tinal barrier compared to the use of cell-culture models in 
which only few types of cells are present compared to the real 
tissue.[34] Hence, to mimic the in vivo situation as much as pos-
sible, intestinal transport studies were also carried out using 
porcine intestinal tissue in a side-by-side diffusion chamber.
Macromol. Biosci. 2019, 1900004
Figure 4. The transport of lysozyme across a) Caco-2 and c) Caco-2/HT29-MTX-E12 cell monolayers is shown for the bulk lysozyme powder and C10 
and microcontainers coated with PLGA, PLGA+PEG, or PLGA+chitosan. From these values the lysozyme flux values were calculated and shown in 
b) for the transport across Caco-2 cell monolayer and in d) for Caco-2/HT29-MTX-E12 cell monolayers. The graphs represent mean + SEM (n = 3).
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The absorption of lysozyme was insufficient for chitosan 
coatings and a flux could not be calculated. This is believed to be 
caused by the slow release from the chitosan coating, due to the 
formation of the chitosan hydrogel, retaining the lysozyme.[38] 
This hydrogel behavior was very clear from a visual inspection 
after the experiment. Moreover, it has been shown that chitosan 
can bind and cross-link mucin and mucus gel and therefore, 
delay the diffusion of molecules through the chitosan/mucus 
gel.[39] From the tissue integrity evaluation at the end of the 
experiment (Figure S3, Supporting Information), it is notice-
able that the Papp for PLGA+chitosan is higher than the other 
samples. It is important to note that, even after 180 min, the 
concentration of lysozyme in the donor chamber was ten times 
lower than for the other samples (data not shown) meaning that 
the lysozyme was not fully dissolved yet. This might be due to 
the fact that chitosan and C10 worked as permeation enhancers 
and this might not have any toxicity effect on the cell mono-
layer even though no lysozyme flux was observed. However, a 
flux of lysozyme was detected for the other samples and was 
3.9 ± 0.4 × 10−6 nmol min−1 cm−2 for the control (not coated), 
7.6 ± 1.6 × 10−6 for PLGA, and 5.3 ± 0.3 × 10−6 nmol min−1 
cm−2 for PLGA+PEG (Figure 5). The microcontainers coated 
only with PLGA showed a higher flux probably due to the lower 
thickness of the coating compared to samples coated with the 
second layer of PEG.
3. Conclusion
This work demonstrated that microcontainers can be func-
tionalized by applying two different layers on top of the cavity 
of the microdevices. Since PLGA is known as a degradable 
polymer to enhance the solubility of the protein, it has been 
chosen as first layer. PEG or chitosan represented the second 
layer as mucoadhesive or mucus penetrating polymers. Both 
PLGA+PEG and PLGA+chitosan resulted in homogeneous 
coatings on top of the lysozyme loaded microcontainers. 
The microcontainers with chitosan coating showed a slower 
lysozyme release compared to PLGA+PEG or PLGA coat-
ings. With regard to the ex vivo mucoadhesive studies, it was 
found that the microcontainers coated by chitosan or PEG 
showed a threefold increase in porcine tissue adhesion, com-
pared to the microcontainers without coatings. The in vitro 
studies with Caco-2 and Caco2/HT29-MTX-E12 co-culture 
monolayers and the ex vivo studies did not show transport 
enhancement and confirmed the results from the release 
study: chitosan-coated microcontainers result in a slower 
transport of lysozyme.
In this study, we obtained mucoadhesive microcontainers 
with tunable release for oral protein delivery. The functionaliza-
tion will be further tested in vivo for better understanding.
4. Experimental Section
Materials: Silicon (Si) wafers (4-in, b100N n-type) were provided by 
Okmetic (Vantaa, Finland), and SU-8 2075 and SU-8 developer were 
purchased from Microresist Technology GmbH (Berlin, Germany). 
Lyophilized lysozyme (from chicken egg white, 14.8 kDa) (≥40.000 
units mg−1, 90% purity), PBS tablets, chitosan (low MW 50–190 kDa, 
75–85% deacetylation), PLGA (low MW 7–17 kDa, 50:50 PLA:PGA) 
were obtained from Sigma-Aldrich (St. Louis, MO, USA). 10x Hank’s 
balanced salt solution (HBSS) and sodium bicarbonate were obtained 
from Thermo Fisher Scientific (Hampton, NH, USA), whereas PEG 
(low MW 12 kDa) was purchased from Fisher Scientific (Hampton, 
NH, USA). n-Capric acid C10 was obtained from abcr GmbH 
(Karlsruhe, Germany). 4-(2-hydroxyethyl)-1-piperazineethanesulfonic 
acid (HEPES), bovine serum albumin (BSA), and Dulbecco’s 
Modified Eagle’s Medium—high glucose, acetonitrile, trifluoroacetic 
acid (TFA), dichloromethane (DCM), and acetic acid (100.5%) were 
all acquired from Sigma-Aldrich (St. Louis, MO, USA). D-[1-14C]-
mannitol was obtained from PerkinElmer (Waltham, MA, USA). 
Milli-Q deionized water was provided by a MilliQ Integral Water 
Purification System for Ultrapure Water, produced by Merck Millipore 
(Burlington, MA, USA).
Fabrication of Microcontainers: Microcontainers were fabricated 
in the epoxy-based photoresist SU-8 using a procedure similar to the 
one described earlier.[40,41] A fluorocarbon coating was deposited on 
top of the supporting silicon wafer by plasma polymerization to ease 
the detachment of microcontainers from the chip.[11] The dimensions 
of the microcontainers were measured using an Alpha-Step IQ Stylus 
Profilometer (KLA-Tencor Corporation, Milpitas, USA) and optical 
microscopy. The fabricated microcontainers had an inner diameter of 
232 ± 1 µm and a height of 255 ± 6 µm (mean ± SD, n = 4) (Figure 1a). 
After fabrication, the wafers were cut into squared chips of 1.2 × 1.2 cm 
containing 625 microcontainers using an Automatic Dicing Saw from 
DISCO (Kirchheim b. München, Germany).
Loading of Lysozyme into Microcontainers: To facilitate the loading 
of lysozyme, the received powder was lightly ground in a mortar to 
obtain a fine powder. Lysozyme was carefully mixed with C10 (7:3 
w/w ratio). The ratio between lysozyme and C10 was chosen as 
it was found that this quantity of C10 ensured the opening of the 
tight junctions without cytotoxicity effects on the cell layer (data not 
shown). A shadow mask was attached on top of the chip to cover the 
areas in between the microcontainers and to avoid excess powder in 
these spaces.[42] The fine powder of lysozyme was evenly distributed 
on top of the mask and pressed into the cavity of the microcontainers 
with a brush. The shadow mask was removed together with the 
excess of powder resulting in filled microcontainers. The chips with 
microcontainers were weighted before and after filling to assess the 
amount of loaded powder.
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Figure 5. Flux of lysozyme across ex vivo porcine intestinal tissue. Micro-
containers without coating, with PLGA, and with PLGA+PEG were tested. 
The data are represented as mean ± SEM with n = 4 (microcontainers 
with PLGA+chitosan, n = 3).
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Functionalization of Microcontainers: After loading, the coatings were 
applied onto the cavity of the microcontainers to functionalize them. The 
coating was performed by spray coating with an ExactaCoat Ultrasonic 
Spray System (Sonotek, USA) with an accumist nozzle operating at 
120 kHz. The polymer solutions used were: PLGA (0.7%) in DCM (w/v), 
PEG (0.7%) in DCM (w/v), or chitosan (0.5%) in acetic acid (0.1 m, 
w/v). The PLGA lid was sprayed followed by either PEG or chitosan 
on top (PLGA+PEG or PLGA+chitosan, respectively). Microcontainers 
only with a PLGA lid were also investigated. During the procedure, the 
flow rate was kept at 0.1 mL min−1, together with a generator power of 
1.3 W. Each chip was coated with two alternating spray paths having an 
offset of 1 mm, resulting in a total of 60, 120, or 70 passages for PLGA, 
chitosan, or PEG, respectively. The shaping air, the speed of the nozzle, 
and the distance between the nozzle and the sample are described in 
Table 2. For the aqueous acidic solution used for the chitosan coating, 
the plate underneath the chip was set to a temperature of 40 °C during 
the spraying process.
Morphology Characterization: The samples PLGA+PEG and 
PLGA+chitosan were subjected to X-ray µCT investigations using a 
commercial Zeiss Xradia versa 410 system (Pleasanton, USA) to assess 
the coating morphology. The samples were mounted on a pin such that 
undisturbed 360° access to the sample was obtained. The pre-voltage 
was kept at 60 kV and the power at 10 W. The 4X optical objective was 
chosen resulting in an efficient pixel size of 2.83 µm, 3201 projection 
angles were measured over 360°. The exposure time for each projection 
was 4 s and the total scanning time 5 h and 2 min. All collected data 
were reconstructed by the commercial software connected to the 
system which relies on a Feldkamp, Davis, and Kress algorithm,[43] 
based on filtered back-projection algorithm. Three areas from each 
sample were analyzed to obtain a more representative image of the 
whole chip.
The loading and coating processes were investigated using a Tabletop 
Microscope TM3030 (Hitachi High-Technologies Europe GmbH, 
Krefeld, Germany). The samples were observed at a 30° tilt using 15 kV 
and secondary electrons (SE) detector.
Flat silicon chips with a layer of SU-8 on top were sprayed with 
each polymer solution for thickness measurements as described in the 
“Functionalization of Microcontainers” section. However, these were 
only coated on one half, by placing a flat half chip on top. The thickness 
measurements were performed with a KLA-Tencor Alpha-Step IQ stylus 
profilometer (Milpitas, CA, USA) with a scan speed of 50 µm s−1 and 
force of 15.3 mg. Each chip was measured in three different places 
(middle and sides).
In Vitro Drug Release from Functionalized Microcontainers: The 
release of lysozyme from the spray coated microcontainers was 
studied using a µ-DISS profiler (pION INC, Woburn, MA) connected 
to a temperature controlled water bath (Struers Kebo Lab, Rødovre, 
Denmark). The release of lysozyme from the coated microcontainers 
(with PLGA, PLGA+PEG, and PLGA+chitosan) was performed attaching 
each chip to a cylindrical magnetic stirrer and covering it with PBS 
(10 mL of 10 mm) at pH 7.4 at 100 rpm. The temperature was 37 °C 
and the absorbance was measured at 280 nm. The path length of the UV 
probes was 20 mm and each channel was calibrated with concentrations 
ranging from 0.03 to 0.3 mg mL−1. The percentage of release was 
calculated from the known amount of powder loaded per chip. These 
experiments were replicated five to six times for microcontainers coated 
with PLGA, PLGA+PEG, or PLGA+chitosan.
Ex Vivo Mucoadhesion Studies: An ex vivo setup similar to the one 
described in literature[44,45] was used to perform the experiments 
for investigating the mucoadhesion of the coated microcontainers. 
Porcine intestine was obtained from healthy experimental control pigs 
(50–55 kg, 15–16 weeks of age, LYD pigs). Immediately after euthanasia 
of the pigs, the intestines were excised using a scalpel and placed in ice. 
Within 2 h, the tissues were frozen and on the day of the experiment, 
a 5 cm piece was cut longitudinally and placed on the supporting slide 
with the apical side facing upward. The mucosal side visually looked 
intact including the mucus layer as the intestine was frozen without 
preparation.
A pump (Watson Marlow, Falmouth, UK) was used to apply a 
peristaltic flow of PBS buffer (10 mm) at pH 7.4. The used setup was 
temperature and humidity controlled with a temperature of 37 °C 
and relative humidity of 80% (Figure S1, Supporting Information). 
Initially, the loosely adhering mucus was washed away for 1 min with 
a flow of 10 mL min−1. After coating the chips, the microcontainers 
were gently manually scraped off the silicon chip. A defined amount 
of microcontainers (177 ± 35) were applied onto a spatula to ease 
the placement of them on the middle of the porcine intestinal tissue 
(in the flow path). Therefore, the orientation of the microcontainers 
on the tissue was random. Subsequently, a flow of 10 mL min−1 was 
applied for 5 min, after which the intestine was left to dry for 24 h. 
The remaining microcontainers were counted using a Leica S9E stereo 
microscope (Leica, Wetzlar, Germany) to determine the percentage of 
microcontainers that adhered to the intestinal tissue at the end of the 
experiment. This experiment was repeated with three different pieces of 
tissue for every type of sample (empty microcontainers, microcontainers 
with PLGA, PLGA+PEG, and PLGA+chitosan coatings).
In Vitro Transport Studies: The Caco-2 (HTB-37) cell line and HT29-
MTX-E12 cell line were acquired by American Type Culture Collection 
(Manassas, VA, USA) and Inserm (Paris, France), respectively. The 
Caco-2 and the HT29-MTX-E12 cells were used in the number of 
passages of 37–43 and 65–71, respectively and co-culture monolayers 
were seeded in a 1:1 ratio of the two cell lines. All the cells were 
cultured as described by Natoli et al.,[46] and transport experiments were 
performed on polarized cells after 21 days on polycarbonate Transwell 
filters with a surface area of 4.67 cm2 and 0.4 µm pore size (Corning 
Costar from Sigma-Aldrich, St. Louis, MO, USA). In vitro transport 
studies were carried out in six well plates, and before the experiment, 
each plate was left at room temperature for 20 min. Subsequently, TEER 
was measured using an Epithelial Volt/Ohm Meter (EVOM) (World 
Precision Instruments, Sarasota, FL, USA) with Endohm chambers for 
each well and all wells were afterward washed twice with HBSS buffer 
(1X HBSS, HEPES (10 mm), BSA (0.05% w/v), sodium bicarbonate 
(0.04% w/v)) with a pH of 7.4. Following this, HBSS buffer was added on 
the apical side (1.5 mL) and to the basolateral side (2.6 mL). Each chip 
was then gently placed upside down directly onto the cell layers. The 
experiment was initiated when the plates were put on a table shaker set 
at 75 rpm and 37 °C. Samples were taken (100 µL), and the volume was 
replaced with pre-heated HBSS, from the basolateral side at specific time 
points of 15, 30, 45, 60, 90, and 120 min. A single sample was also taken 
from the apical side after 120 min to normalize the release of proteins in 
the data analysis. After the 2 h runtime, the chips were gently removed. 
The cells were washed twice with HBSS buffer and TEER values were 
measured again. All samples were frozen at −20 °C and analyzed with 
the RP-HPLC methods described in “Reversed-Phase High-Performance 
Liquid Chromatography (RP-HPLC) method.” The lysozyme flux (F) [mol 
cm−2 s−1] was calculated according to Equation (1).
F
dQ
dt A
1
= ⋅  (1)
where dQ/dt [mol s−1] is the rate of lysozyme permeation and A is 
the area of the inserts (4.67 cm2). All the experiments were done in 
triplicates.
Ex Vivo Transport Studies: Ex vivo transport studies were performed 
using a modular EM-CSY-8 Ussing chamber system (Physiologic 
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Table 2. Parameters used for spray coating PLGA, chitosan, and PEG 
onto the cavity of microcontainers.
PLGA Chitosan PEG
Shaping air [kPa] 0.03 0.01 0.03
Nozzle speed [mm s−1] 10 25 10
Distance between the nozzle and the 
sample [mm]
50 25 50
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Instruments, San Diego, CA, USA) including a temperature-controlled 
metal rack for mounting Ussing chambers in series. Ussing chambers 
containing a vertical port were assembled and mounted onto the rack. 
A slider was inserted between each pair of chambers and a volume 
of HBSS buffer (2 mL) at pH 7.4 was added to each chamber. The 
metal rack was pre-heated to equilibrate the system until the buffer 
in the chambers reached 35–37 °C. Moreover, humidified airflow was 
applied to each chamber. A piece of porcine intestine was carefully 
stripped to remove the serosa and the longitudinal and circular muscle 
layers of the intestine.[47] After equilibration, the buffer was removed, 
the chambers were dried, and the slider was taken out. A small cut of 
stripped intestine was carefully stretched and mounted into the slider 
by impaling the edges of the intestine on a circle of small metal pins 
around the aperture. Loaded and coated microcontainers were scraped 
off and gently applied onto the apical side of the intestine before the 
slider was re-inserted into the Ussing chambers. Pre-heated HBSS 
buffer (2 mL) pH 7.4 was then added to each chamber. Samples were 
taken from the receptor side (100 µL) at 30 min time intervals from 0 to 
180 min. A single sample was also taken from the donor side (100 µL) 
at 0 and 180 min. All samples were analyzed with RP-HPLC described 
in “Reversed-Phase High-Performance Liquid Chromatography 
(RP-HPLC) method” and the flux was calculated as described in the 
“In Vitro Transport Studies” section. Following each ex vivo transport 
experiment, the integrity of the porcine intestine was evaluated by 
the flux of radioactive D-[1-14C]-mannitol. A HBSS buffer with D-[1-
14C]-mannitol (0.1 mm) was prepared, and the solution (2 mL) was 
added to the apical side and regular HBSS buffer was added to the 
basolateral side (2 mL). Three samples (of each 100 µL) were taken at 
0 and 60 min from both the apical and basolateral side. Three samples 
were also taken from the original D-[1-14C]-mannitol (0.1 mm) HBSS 
buffer solution. Ultima Gold Scintillation fluid (2 mL) was added 
to each sample, vortexed, and analyzed by a scintillation analyzer 
(PerkinElmer, Tri-Carb 2910 TR). The apparent permeability coefficient 
(Papp) [cm s−1] has been calculated according to Equation (2).
P
dQ
dt A C
F
Capp
1
0 0
= ⋅
⋅
=  (2)
where dQ/dt [mol s−1] is the rate of lysozyme permeation, A is the area 
of the inserts (0.78 cm2), C0 [mol cm−3] is the initial donor concentration 
of D-[1-14C]-mannitol, and F is described in Equation (1).
All the experiments were repeated four times per sample type except 
for the microcontainers coated with PLGA and chitosan which were 
tested in triplicate.
Reversed-Phase High-Performance Liquid Chromatography Method: 
Samples obtained from the in vitro and ex vivo transport studies 
were analyzed by RP-HPLC on a Prominence Ultra-Fast Liquid 
Chromatography (UFLC) instrument system (Shimadzu, Japan). 
The column used was a Kinetex 5 µm XB-C18 (100 Å, 100 × 4.6 mm) 
(Phenomenex, USA). The mobile phases were acetonitrile with TFA 
(0.1%, v/v) (solvent A) and MilliQ deionized water with TFA (0.1%, v/v) 
(Solvent B) at 30 °C and solvent A had a steady gradient from 29% to 
71% over 15 min at a flow rate of 1.4 mL min−1, and the absorbance 
was measured at 280 nm. RP-HPLC has been used also to verify the 
integrity of the protein after grinding and leaving it at room temperature 
for 1 week (data not shown).
Statistical Analysis: Data is expressed as mean ± standard error of the 
mean (SEM) for ex vivo mucoadhesion studies and ex vivo and in vivo 
transport studies. Mean ± standard deviation (SD) has been used in all 
the other data analysis. p-values are calculated using the unpaired t-test 
in GraphPad Prism (GraphPad Software, CA, USA) and were considered 
statistically significant when below 5% (p < 0.05).
Supporting Information
Supporting Information is available from the Wiley Online Library or 
from the author.
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Figure S1: Schematic representation of the ex vivo mucoadhesion setup. Pig intestine is 
placed on a slide and flushed with a peristaltic pump. The temperature and humidity are 
controlled. 
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Figure S2: TEER values measured before and after the experiments for the blank, 
microcontainers coated with PLGA, PLGA+PEG and PLGA+chitosan. These were done with 
a) Caco-2 cell monolayer and b) Caco-2/HT29-MTX-E12 cell monolayers (mean ± SD, n = 3).  
 
 
Figure S3: Papp of D-[1-14C]-mannitol calculated after the ex vivo transport studies comparing 
the microcontainers without coating with the ones with only PLGA, PLGA+PEG and 
PLGA+chitosan. All the values are represented as mean ± SD, n = 2-4. 
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Microcontainers are polymeric cylindrical microdevices designed for oral drug deliv-
ery. They have an external diameter and a height of approximately 300 µm. Con-
trary to the omni-directional release that is characteristic for oral drug formulations 
like tablets, capsules and particulate systems, the unidirectional release provided 
by microcontainers avoids loss of the drug in the lumen. In this project, the work 
focused on two main aspects i) loading techniques of drugs into microcontainers for 
enhancing oral delivery of poorly water soluble drugs and ii) coating the cavity of 
microcontainers in order to functionalize these for increasing the oral absorption of 
proteins. This project showed a promising potential for microcontainers as oral deliv-
ery system for poorly soluble drugs and proteins. 
